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Deciphering the roles of ΔNp63 in regulating epithelial to mesenchymal 
transition, cancer progression and metastasis 
 
Ngoc Hoang Bao Bui, M.S. 
 
Advisory Professor: Elsa R. Flores, Ph.D. 
 
p63 is a member of the p53 family, a well-known tumor suppressor which is 
considered the guardian of the genome. The TP63 gene encodes multiple isoforms 
that can be categorized into two main isoforms, TAp63 and ΔNp63, which are 
expressed in different cellular compartments and have distinct functions in many 
biological processes. While the Flores laboratory identified TAp63 as a tumor and 
metastasis suppressor, the precise roles of ΔNp63 isoforms in tumorigenesis and 
metastasis remain elusive. ΔNp63 is the predominant p63 isoform expressed in the 
epidermis and plays essential roles in regulating epidermal development and 
homeostasis. Utilizing a ΔNp63-conditional knockout mouse model generated in the 
Flores lab, I demonstrated that the loss of ∆Np63 in basal epidermal cells elicits an 
“irreversible” epithelial to mesenchymal transition (EMT) via activation of 
transcription factors Twist1 and Lef1, leading to a delay in wound healing process in 
vivo. I further identified the involvement of a ∆Np63/miR-98, miR-34a/Twist1, Lef1 
axis in the regulation of EMT in epidermal cells and wound healing. Moreover, my 
work revealed pleiotropic roles of ΔNp63 as either a tumor suppressor or an 
oncogene in tumor development and progression. Further, I showed that ΔNp63 
  
vii  
activates its oncogenic program through transcriptional regulation of Lef1 in breast 
cancer and lung squamous cell carcinoma. Finally, by generating an in vivo ΔNp63-
inducible knockdown system, I demonstrated that a dynamic regulation of ΔNp63 
enhances metastatic dissemination in breast cancer. Additional work revealed a 
TGFβ/microRNAs axis in modulating ΔNp63 expression in breast cancer. The 
activation of canonical Smad-dependent TGFβ signaling down-regulates expression 
of ΔNp63 via a network of TGFβ-induced microRNAs, including miR-22-3p, miR-
30a-5p, miR-203a-3p and miR-222-3p. These microRNAs cooperatively function to 
regulate expression of ΔNp63 downstream of TGFβ signaling in breast cancer. 
Taken together, my work clarified complex context-dependent roles of ΔNp63 in 
modulating EMT, cancer progression and metastasis. These findings revealed novel 
regulatory networks of ΔNp63 in normal wound repair and cancers, which are 
particularly beneficial for the development of diagnostic biomarkers and therapeutic 
interventions for chronic wounds and metastatic cancers.  
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Chapter 1: Introduction 
1.1 p63, a member of p53 protein family 
1.1.1 An overview 
The discovery and cloning of TP63 gene, a homolog of the tumor suppressor 
TP53, in 1998 has brought enormous attentions to lesser known members of the 
p53 family (1). The first p63 knockout (TP63-/-) mouse models were generated and 
characterized with striking defects in limb, craniofacial and epithelial development, 
which prompted a question on the significance of this p53 family member during 
normal development and diseases (2, 3). Since its discovery 20 years ago, there 
have been numerous studies focusing on investigating its structure and functions in 
many physiological and pathological processes. However, the TP63 locus has a very 
complex structure with two separate promoters and multiple alternative splicing, 
resulting in transcription of at least six different isoforms. This complexity has 
challenged studies that aim to fully understand specific functions of each isoform in 
biological processes and diseases, including cancers (4).  
Initial reports on p63 expression in human cancers led to contradictory 
findings on whether p63 was a tumor suppressor or oncogene due to structural 
complexity at the TP63 locus (4). Isoform-specific conditional knockout mouse 
models for TAp63 and ΔNp63 have elucidated distinct roles of p63 isoforms in 
different cellular compartments, emphasizing the importance of investigating specific 
isoforms during the initiation and progression of diseases (5-7).  
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1.1.2 p63 structure and homology to other p53 family members 
The TP63 gene locates at chromosome 3q27–29 and encodes an acidic N-
terminal transactivation (TA) domain, a DNA-binding domain (DBD) and a carboxy-
oligomerization domain (OD) (1, 8, 9). The DBD shares the highest homology with 
other members of the family (more than 60% identical with p53 and around 85% 
identical with p73). Therefore, p63 is able to bind and activate transcription from 
canonical p53-responsive elements. Importantly, these structural similarities also 
account for complex interactions among p53, p63 and p73, indicating an intricate 
relationship among p53 family members in development and diseases. The TA 
domain is the least conserved among p53, p63 and p73 with less than 30% 
homology (Figure 1) (4, 8).  
As mentioned before, the TP63 gene contains two different promoters, which 
results in the transcription of multiple proteins categorized into two main isoforms, 
TAp63 (with a TA domain) and ΔNp63 (without a TA domain) (9). In addition, both 
TAp63 and ΔNp63 transcripts can be transcribed into proteins with at least three 
different C-termini termed α, β and γ via alternative splicing. The full-length α 
isoforms (TAp63α and ΔNp63α) contain a carboxy-terminal sterile α-motif (SAM) 
domain, a protein-protein interaction domain that has been implicated in many 
cellular processes. It has been reported that TP53 and TP73 genes can also 
transcribe into multiple isoforms through separate promoters and alternative splicing, 
adding more layers to the complexity and functional diversity of the family (8-10).  
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Figure 1: p53 family members share structural similarities. p63 and p73 share 
high structure similarities to p53, especially with more than 60% at the DNA-binding 
domain (DBD). p63 and p73 express multiple isoforms which are characterized into 
two main categories: TA isoforms and ΔN isoforms. Through alternative splicing, 
TP63 and TP73 genes can be transcribed into proteins with at least three different 
C-termini termed α, β and γ.  
(Figure is reproduced from Su X, Chakravarti D, Flores ER. p63 steps into the 
limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev 
Cancer. 2013; 13(2):136-43, with permission from Copyright Clearance Center) 
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1.1.3 TAp63 versus ∆Np63, a tale of two isoforms 
Due to significant homology to p53 at the DBD, p63 was predicted to have 
transcriptional activities on p53 target genes. Initial in vitro studies showed that 
TAp63 isoforms can transactivate p53 targets, whereas ∆Np63 isoforms were 
thought to have dominant-negative effects on p53- and TAp63- mediated 
transcription due to the lack of the TA domain (1, 11). However, an increasing 
number of studies have demonstrated that ∆Np63 has its own transactivation 
domain at the C-terminal end and is able to induce transcription of its own target 
genes (12-14).  
Even though these two isoforms are derived from the same gene locus, they 
are expressed in different cellular compartments and have distinct functions in many 
biological processes. While TAp63 knockout (TAp63-/-) mice were viable with shorter 
lifespan than wild-type mice and developed spontaneous metastatic tumors, ∆Np63 
knockout (∆Np63-/-) mice were born with severe defects in epidermal differentiation, 
limb and craniofacial development, and died shortly after birth (5, 7, 15). The 
predominant isoform expressed in the basal layer of the epidermis is ∆Np63. Several 
studies have shown that ∆Np63 maintains the proliferative potential of basal stem 
cells, and that loss of ∆Np63 expression in these cells causes disruption in the 
proper differentiation of the epidermis (4, 5, 10). ∆Np63 also localizes in basal cells 
of the epithelial tissues in mammary glands, trachea, cervix, prostates, tongue and 
hair follicles (9). TAp63, on the other hand, is found at very low level in the epidermal 
compartment of the skin and acts as a molecular switch during epithelial stratification 
program. TAp63 is expressed very early at day E7.5 in mouse embryos, then get  
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Figure 2: TAp63 and ∆Np63 are expressed in different cellular compartments 
in the skin. ∆Np63 is the predominant isoform expressed in the basal layer of the 
epidermis. TAp63 isoforms are expressed in a specific subset of dermal stem cells 
known as skin-derived precursor cells (SKPs), and regulates expression of CDKN1C 
to prevent premature senescence.  
(Figure is reproduced from Su X, Chakravarti D, Flores ER. p63 steps into the 
limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev 
Cancer. 2013; 13(2):136-43, with permission from Copyright Clearance Center) 
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turned off by ∆Np63 to allow maturation of the epidermis during 
embryogenesis (16).  In stratified epithelium, TAp63 isoforms are expressed in a 
specific subset of dermal stem cells known as skin-derived precursor cells (SKPs) 
and maintain these cells in quiescence to prevent genomic instability and premature 
senescence (Figure 2). TAp63-/- mice developed accelerated aging phenotype, 
spontaneous blisters, skin ulceration and delayed wound healing due to premature 
depletion of dermal and epidermal precursors (6). Taken together, these findings 
suggest distinct contributions of TAp63 and ∆Np63 during development. 
p53 is a well-known tumor suppressor for its roles in promoting cell cycle 
arrest, cellular senescence and apoptosis through its transcriptional activities on 
p21, retinoblastoma (RB) and Bcl-2 family member (17). Due to high structural 
similarities between p63 and p53, together with the ability of p63 to activate p53-
target genes, p63 was initially believed to function as a tumor suppressor. 
Interestingly, while TP53 is widely mutated across multiple cancers and TP53 
mutation is considered one of the hallmarks of cancers, TP63 is rarely mutated and 
frequently found to be overexpressed in multiple epithelial cancers. However, these 
studies often failed to distinguish between TAp63 and ∆Np63 isoforms (18, 19). 
Early genetic mouse models demonstrated that TP63 heterozygous (TP63+/-) mice 
had shorter lifespan than their wild-type littermates and developed various types of 
tumors, including squamous cell carcinomas, thymic lymphoma, lung 
adenocarcinomas and hemangiosarcomas. Interestingly, double mutant TP53+/-; 
TP63+/- mice exhibited a more aggressive tumor phenotype with higher metastatic 
frequency compared to TP53+/- mice, suggesting an important tumor suppressive 
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role of p63 in cancer development and metastasis (20). In another mouse model, 
TP63+/- mice showed a significant decrease in spontaneous tumors compared to wild 
type mice. Features of accelerated aging and hyperplasia in the epithelium were 
often observed in these mice. In this case, TP53+/-; TP63+/- mice had lower tumor 
incidence than TP53+/- mice, proposing TP63 as an oncogene in cancers (21). These 
contradictory results arose from the existence of multiple p63 isoforms with potential 
opposing functions and the lack of isoform specific knockout mouse models.  
The first TAp63 knockout (TAp63-/-) mouse model was reported to develop 
spontaneous metastatic carcinomas and sarcomas. Strikingly, TAp63 heterozygous 
(TAp63+/-) mice displayed a higher metastatic frequency in sarcomas than TAp63-/- 
mice, whereas TAp63-/- and TAp63+/- mice had a similar metastatic frequency in 
carcinomas, indicating a tissue-specific contribution of loss of heterogeneity (LOH) in 
the aggressiveness of cancers. Moreover, TAp63 was shown to control metastasis 
through direct transcriptional activation of Dicer and miR-130b. Overexpressing 
Dicer and miR-130b in TAp63-deficient mouse embryonic fibroblasts (MEFs) 
decreased migratory and invasive capacity of these cells (15). In another 
independent study, TAp63 was also demonstrated as a suppressor of tumorigenesis 
in vivo through inducing senescence via oncogenic Ras, and this activity was 
independent of p53 (22). Through several in vitro studies, TAp63 has been shown to 
not only be induced upon DNA damage but be able to activate transcriptions of 
genes involved in apoptosis (23, 24). Recent in vivo data also revealed tumor 
suppressive functions of TAp63 in thymic lymphoma through metabolic 
reprogramming via direct transcriptional activation of IAPP (25). Further, 
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unpublished data from the Flores lab have unveiled a novel regulatory network of 
TAp63 and long non-coding RNAs (lncRNAs) in suppressing tumorigenesis and 
metastasis in breast cancer. In summary, these data confirmed TAp63 as a 
suppressor of tumorigenesis and metastasis (Figure 3A).  
The fact that ∆Np63-/- mice die shortly after birth was a major challenge for 
studies that aimed to understand the roles of this isoform in tumorigenesis and 
metastasis. Due to its antagonistic effects on transcriptional activities of p53, TAp63 
and TAp73, ∆Np63 has been implicated as an oncogene in cancers (1, 4). ∆Np63 is 
highly expressed in lung and head and neck squamous cell carcinomas (12, 18, 26). 
Moreover, a recent in vivo study utilized a ∆Np63 conditional knockout mouse model 
to demonstrate that the ablation of ∆Np63 suppresses thymic lymphomas in p53-
deficient mice through TAp63-induced transcription of IAPP (25). Napoli et al further 
explored oncogenic activities of ΔNp63 through ΔNp63/DCGR8/microRNAs axis and 
utilized HDAC inhibitors to induce tumor regression in both thymic lymphomas and 
cSCC (27). These accumulating data further emphasize potential oncogenic 
activities of ∆Np63 in cancers. However, there are evidences that ∆Np63 is a 
suppressor of epithelial to mesenchymal transition (EMT) and potentially cancer 
metastasis (28-31). Metastasis suppressive functions of ∆Np63 was also connected 
to its inhibitory effects on Erk signaling pathway (29). Interestingly, ΔNp63 was 
shown to promote breast cancer cell migration and invasion via transcriptionally 
regulating MTSS1 (32). Together, these data indicate that functions of ∆Np63 in 
cancer development and metastasis are far more complex (Figure 3B). 
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Figure 3: Functions of TAp63 and ∆Np63 in tumorigenesis and metastasis. A, 
TAp63 as a tumor suppressor of tumorigenesis and metastasis through various 
mechanisms, including metabolic reprogramming via IAPP, regulation of microRNA 
biogenesis via Dicer and modulation of novel long non-coding RNAs (lncRNAs). B, 
Pleiotropic roles of ∆Np63 as either an oncogene or tumor suppressor in 
tumorigenesis and metastasis.      
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1.2 ∆Np63 in epithelial development  
1.2.1 Epithelial stratification 
The skin is the primary barrier to protect the body from dehydration, 
environmental insults and pathogens. It is comprised of two compartments, the 
dermis and the epidermis that function cooperatively to regulate epithelial 
stratification and homeostasis. The epidermis is separated from the dermis by 
structure known as the basement membrane. The epidermis is continuously 
regenerated by proliferative keratinocytes in the basal layer. The epidermis also 
provides a variety of appendages throughout the whole body, including mammary 
glands, sweat glands and hair follicles (33-35).  
The stratification program starts as early as day E8.5 during embryogenesis 
when cells in the ectoderm receive signals to switch to an epidermal fate (33). After 
this commitment, basal keratinocytes in the single-layer epidermis begin parallel 
divisions to expand the epidermal area. Then, a large portion of these cells start to 
divide asymmetrically perpendicular to the basement membrane to generate one 
basal and one intermediate suprabasal daughter cell. Later, these intermediate cells 
mature into spinous cells which further undergo terminal differentiation into granular 
and cornified cells (33, 36) (Figure 4). These epidermal cells not only have different 
morphology but express distinct sets of cytokeratin markers. Basal keratinocytes 
express keratin 5 (K5) and keratin 14 (K14), whereas suprabasal cells express 
keratin 1 (K1) and keratin 10 (K10) (33). Skin stratification is a very complex process 
orchestrated by various signaling factors and coordination between multiple cell  
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Figure 4: Structure of the epidermis. The skin epidermis comprises of 4 main 
layers: basal, spinous, granular and stratum corneum layers. The epidermis is 
separate from the dermis by a basement membrane.  
(Figure is reproduced from Gonzales KAU, Fuchs E. Skin and Its Regenerative 
Powers: An Alliance between Stem Cells and Their Niche. Dev Cell. 2017;43(4):387-
401, with permission from Copyright Clearance Center) 
 
 
 
 
 
 
 
 
  
13  
populations, especially the tissue-resident stem cells with self-renewal capacity, in 
order to maintain structural integrity and homeostasis of the skin (36).  
 
1.2.2 The roles of ∆Np63 in epithelial development 
∆Np63-/- mice were born with severe developmental defects in epithelial 
stratification and died shortly after birth due to dehydration, which resembled 
phenotype of TP63-/- mice (5, 7). While TAp63 is the first isoform to be expressed in 
the single-layer epidermis and required for initiation of a stratification program 
through activation of K14 expression, ∆Np63 is the most abundant isoform found in 
the basal layers of stratified epidermis and essential for both maintenance of 
resident stem cell population in the epidermis and terminal differentiation of 
epidermal cells (16, 33-35). Moreover, only crossing ∆Np63α-overexpressing 
transgenic mice, but not TAp63α, to the TP63-/- mice was able to partially rescue the 
epithelialization of the epidermal layer (37, 38).  
In one study, ∆Np63-null keratinocytes exhibited unbalanced and accelerated 
differentiation, resulting in a failure to form a mature stratified epithelium. There were 
keratinocytes expressing K5 in a patchy fashion in the ∆Np63-null skin, indicating 
that a subset of ∆Np63-deficient keratinocytes were still able to commit to an 
epidermal fate. Interestingly, clusters of keratinocytes were found not only to express 
K5 but to retain expression of K8 as well. Co-expression of K5, K1 and K10 was also 
found in the epidermal layer of E15.5 ∆Np63-null embryos. These findings suggest 
an altered differentiation program associated with premature expression of terminal 
differentiation markers in ∆Np63-null keratinocytes. Furthermore, this study 
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demonstrated that ∆Np63-null skin showed a significant decrease in cell 
proliferation, loss of extracellular matrix and alterations in Notch signaling pathway 
(5). Another study utilizing a ∆Np63 conditional knockout mouse model found that 
∆Np63-null epidermal cells simultaneously expressed multiple differentiation 
markers, including K8, K18, K14 and K10, indicating defects in terminal 
differentiation in these cells. However, these ∆Np63-null epidermal cells displayed 
hyperproliferation with increased BrdU incorporation and self-renewing capacity with 
high expression of induced-pluripotency associated factors such as Oct4, Sox2 and 
Nanog. ∆Np63 is believed to regulate multipotency in keratinocytes through 
transcriptional activation of DGCR8, a component of the microRNA biogenesis 
machinery (7). Taken together, although there are conflicting data on how ∆Np63 
regulates proliferation in keratinocytes, it is evident that ∆Np63 is a master regulator 
of epithelial development.  
One of the important molecular switches that has been shown to control 
∆Np63 level between epidermal proliferation and differentiation is microRNA-203 
(miR-203). In situ hybridization of miR-203 in the skin showed that miR-203 was 
mainly expressed in the suprabasal layer, but not in the basal layer. This expression 
pattern was mutually exclusive with ∆Np63 (39). Similarly, human keratinocytes 
induced differentiation by calcium treatment in vitro had higher level of miR-203 and 
lower level of ∆Np63 than untreated cells. ∆Np63 was shown to be a direct target of 
miR-203 during epidermal terminal differentiation (39, 40).  
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1.3 ∆Np63 in epithelial to mesenchymal transition (EMT) 
1.3.1 The regulatory network of EMT 
Since its first description in the early 1980s, the concept of EMT has emerged 
as an integral mechanism in many physiological and pathological processes, such 
as gastrulation, morphogenesis, wound repair, cell adhesion and movement, fibrosis 
and especially cancers (41, 42). Epithelial cells are single layer (or multilayer) cells 
that are closely in contact with each other through various structures on cellular 
membranes, including adherens junctions, tight junctions, gap junctions and 
desmosomes. In addition, epithelial cells show apical-basolateral polarization based 
on arrangement of cadherins and integrins on the basement membrane, and 
communicate with each other through specialized junctional complexes. 
Mesenchymal or stromal cells, on the other hand, neither organize into cell layers 
nor exhibit apical-basal cell polarity. Mesenchymal cells in culture display spindle 
shapes with high motility (41, 43-45). 
EMT is a process in which epithelial cells undergo changes in their cell 
morphology to acquire characteristics of mesenchymal cells, including enhanced cell 
motility and invasion. Specifically, EMT typically results in the loss of cell-cell 
contacts and is associated with decreased expression of epithelial markers, 
including E-cadherin and occludins. Conversely, the expression of mesenchymal 
markers, such as N-cadherin and Vimentin are increased during EMT (45, 46). The 
reverse process, in which mesenchymal cells transform into a more epithelial state, 
is known as the mesenchymal to epithelial transition (MET). These findings suggest 
a dynamic nature of EMT to allow cells to transition between the two states of  
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Figure 5: The reversible nature of EMT. EMT is a reversible program in which 
cells can switch between epithelial and mesenchymal state. Epithelial cells undergo 
EMT to become mesenchymal cells. Conversely, mesenchymal cells undergo MET 
to reverse to epithelial state. EMT and MET processes are highly regulated by a 
complex network of transcription factors. 
(Figure is reproduced from Thiery JP, Sleeman JP. Complex networks orchestrate 
epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131-42, with 
permission from Copyright Clearance Center) 
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epithelial and mesenchymal in a highly plastic fashion (41, 47) (Figure 5). There are 
three distinct types of EMT based on different biological contexts that EMT is 
involved. Type 1 EMT happens during embryogenesis, gastrulation, organ 
morphogenesis and development. Type 2 EMT is related to normal wound repair, 
tissue regeneration and organ fibrosis. Type 3 EMT is involved in cancer and 
metastasis where tumor cells gain mesenchymal phenotype, allowing them to invade 
local stroma and metastasize to distant organs (45). 
EMT is mediated by a complex regulatory network of transcription factors, 
signaling molecules, and microRNAs. Several transcription factors have been 
demonstrated to function as master drivers of EMT, including Twist1/2, Snail1/2 and 
Zeb1/2. These transcription factors activate an EMT program by inhibiting epithelial 
markers and activating mesenchymal ones through various mechanisms (47-49). 
Twist1 binds to E-boxes in the promoter of E-cadherin to repress its transcription 
(49). Twist1 interaction with the NuRD complex or polycomb repressor complexes, 
PRC1 and PRC2, is also required for the suppression of E-cadherin (50-52). 
Likewise, Twist1 induces N-cadherin expression through direct transcriptional 
activation (53). Similarly, Snail1 (Snail) and Snail2 (Slug) inhibit E-cadherin 
transcription by recruiting polycomb repressor complex 2 (PRC2) to its promoter (54-
56). In addition, Snail and Slug suppress expression of several other epithelial 
markers such as cytokeratins, occludins, claudins and desmoplakin, whereas they 
increase expression of pro-invasive genes such as vimentin and fibronectin (49, 57). 
Snail also binds to Smad3/4 proteins to promote EMT in the presence of TGFβ (58). 
In certain contexts, Snail and Twist factors can cooperate to regulate a same set of 
  
18  
genes involved in EMT. Interestingly, Zeb1 and Zeb2 are downstream targets of 
both Snail and Twist (48, 49, 59). Several signaling pathways, such as Wnt, TGFβ, 
Notch, FGF, TNFα and tyrosine kinase receptors, can directly upregulate Twist, 
Snail and Zeb factors. These findings suggest an intricate cross-regulatory network 
among EMT-inducers to promote cell migratory and invasive abilities (41, 49).  
Recently, microRNAs have been intensively demonstrated as integral post-
transcriptional regulations of EMT and MET. A complex network of microRNAs 
(miRs) has been involved in controlling translation of multiple EMT-associated 
factors. Conversely, Twist, Snail and Zeb can also regulate expression of EMT-
related microRNAs, establishing a negative feedback loop to maintain epithelial 
homeostasis (60, 61). Among the microRNAs governing EMT, miR-200 and miR-205 
families stand out. miR-200 and miR-205 members have been shown to directly bind 
to 3’UTR of Zeb1 and Zeb2 to repress their expression (62). In turn, miR-200 family 
is inhibited by not only Zeb1/2 but Snail1 to form a double negative feedback loop 
(63, 64). Similarly, while Snail1 is a direct target of miR-34 and miR-203, it also 
binds to E-boxes in the promoters of miR-34 and miR-203 to regulate their 
expression (65, 66). Twist1 has been shown to be repressed by let-7d, miR-29b and 
miR-214 (67-69). miR-10b, an onco-microRNA highly expressed in metastatic breast 
cancer, is a direct target of Twist1 (70). Furthermore, there are other aspects of EMT 
regulated by microRNAs. For example, miR-9 directly targets E-cadherin in 
mammary epithelial cells to induce EMT and increase invasiveness (71).  
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1.3.2  EMT in wound healing 
Wound healing is a physiological response to injury in order to re-establish 
normal architecture of the epithelium. The process of wound repair consists of three 
partially overlapping but distinct phases: inflammation, formation of new tissue and 
tissue remodeling (72, 73). During wound healing, keratinocytes at the migratory 
front of the wound undergo morphological and behavioral changes to acquire a more 
motile phenotype, and move toward damaged area in a process called re-
epithelialization. This intermediate state allows the cells to undergo a “partial” EMT 
and gain motility to heal the wound while maintaining loose cell-cell contact. At the 
end of the re-epithelialization process, these “metastable” cells are able to reverse to 
their original epithelial state in order to fully cover the wound with a new epithelial 
sheet due to plastic nature of the “partial” EMT (43, 47, 74). Snail2 has been shown 
to be involved in triggering the “partial” EMT during wound repair. Upon EGF 
treatment in keratinocytes, Erk5 is phosphorylated and induce expression of Snail2, 
driving the re-epithelialization process in vitro (75). As such, Snail2-deficient mice 
displayed defects in wound healing (76). In addition, in a N-
Acetylglucosaminyltransferase-V (GnT-V) transgenic mouse model, the upregulation 
of Twist and Snail enhanced wound repair process in vivo (77).  
 
1.3.3 EMT in cancer progression and metastasis 
Metastasis is a rare occurrence of tumor cells in which they lose contact with 
surrounding cells due to the loss of cell-cell adhesions, enter into circulation, and 
successfully infiltrate and form metastases at distant organs. EMT has been shown 
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to strongly associate with the progression and metastasis of multiple cancers (19, 
43, 46). As a key player in metastasis, the EMT program confers malignant traits 
associated with invasiveness onto epithelial tumor cells to initiate metastatic 
dissemination (78, 79). In addition, the acquisition of stem cell characteristics in 
tumor cells after induction of EMT has been observed in multiple cancers, further 
confirming the necessity of EMT in cancer stem cell formation and tumor 
dissemination (80-85). More importantly, the MET is believed to be essential for 
circulating tumor cells to proliferate and seed new tumors at distant organs, 
revealing the importance of a “reversible” EMT in the multistep process of metastatic 
cascade (86, 87). Two independent studies have shown that while EMT triggers the 
dissemination of tumor cells, MET facilitates colonization and establishment of 
distant metastases in vivo through two different EMT-associated transcription 
factors. Tsai et al. demonstrated in a spontaneous squamous cell carcinomas 
mouse model that the spatiotemporal regulation of EMT and MET through Twist1 
has a significant role in increasing number of circulating tumor cells in the circulation 
and subsequently metastatic frequency (87). Ocana et al., on the other hand, 
identified homeobox factor Prrx1 as a novel EMT-inducer.  In this study, Prrx1 has 
been shown to elicit EMT program in both embryos and tumor cells, whereas the 
loss of Prrx1 reverses EMT to MET and increases metastasis. While showing Prrx1 
cooperates with Twist1 in inducing EMT and invasion, the study also pointed out that 
knocking down Prrx1 alone or both Prrx1 and Twist, but not Twist1 alone, was able 
to enhance lung metastasis in a tail vein injection experiment. Strikingly, Prrx1-
depleted non-tumorigenic cells acquired stem cell properties, suggesting evidence 
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for the uncoupling of EMT and acquisition of stemness during cancer metastasis 
(86). However, controversies on whether EMT is a prerequisite for metastasis still 
exist due to the lack of direct evidence tracing natural occurrence of EMT in 
spontaneous cancer metastasis in vivo. 
Recently, the contributions of EMT in cancer progression and metastasis 
have been greatly challenged by in vivo data showing EMT is not required for 
metastasis in several separate mouse models for pancreatic and breast cancers (88, 
89). Utilizing a lineage tracing system for EMT in vivo, Fisher et al. provided 
evidence for a rare occurrence of EMT events in tumor progression in two 
spontaneous metastatic breast cancer models. In this study, a Cre-switchable 
fluorescence marker was used to follow the transition of tumor cells from an 
epithelial (RFP-positive) to a mesenchymal phenotype (GFP-positive) in vivo. Yet, 
the irreversible nature of this system cannot determine whether the GFP-positive 
cells eventually returned to epithelial state. This system showed that tumor cells 
found in lung metastases were RFP-positive, indicating that neither Vimentin or Fsp1 
activated-EMT occurred in these metastatic cells. Further, the authors showed that 
the overexpression of miR-200 to inhibit EMT did not impair the formation of 
metastases in the lungs (88). In another study, Zheng et al. established genetically 
modified pancreatic cancer mouse models to delete two EMT-drivers, Twist1 and 
Snail1, and demonstrated that in vivo depletion of neither Twist1 nor Snail1 had 
significant impact on initiation, progression and metastasis formation in pancreatic 
cancer (89). Interestingly, both of the studies emphasized synergistic effects of EMT 
inhibition and chemotherapy in treatment of metastatic cancers (88, 89).  
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Figure 6: Intermediate states that cells undergo during the transition from 
epithelial to mesenchymal phenotype. During EMT, epithelial cells undergo a 
spectrum of phenotype, from epithelial (E) to multiple intermediate (EM) states, then 
finally reach mesenchymal (M) state. Different sets of transcription factors are 
involved at each step of the transition.  
(Figure is reproduced from Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. 
Cell. 2016;166(1):21-45, with permission from Copyright Clearance Center)    
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Given the heterogeneous and context-dependent characteristics of cancers, 
underlying mechanisms of metastasis may vary across different types and stages of 
cancers. The opposing observations on the roles of EMT in metastatic process 
reflect the complexity of an open question where further investigations are obligatory 
to provide more insights into the issue. Perhaps, instead of a “black and white” 
description of EMT in which cells are either in a full epithelial or mesenchymal state, 
a spectrum of transitional states between epithelial and mesenchymal characteristics 
may provide tumor cells with greater flexibility and plasticity in order to survive, 
proliferate and establish metastatic colonies (47, 79). An increasing number of 
reports have described the existence of a “partial” EMT in which tumor cells stay in 
intermediary phases between epithelial and mesenchymal states and manifest 
characteristics from both phenotypes (90-92) (Figure 6). Cells with this hybrid 
phenotype exhibit a great dynamic potential to spatiotemporally induce or reverse 
EMT, which ultimately favors tumor progression and metastasis (47, 93). 
 
1.3.4 The roles of ∆Np63 in EMT 
A knockdown of p63 in human mammary epithelial cells and keratinocytes 
disrupted cellular adhesion program and increased anoikis, leading to detachment of 
cells from matrix and ultimately cell death. Overexpression of either ∆Np63α or 
TAp63γ rescued the phenotype, suggesting an involvement of ∆Np63 in regulation 
of cell-cell contact, an important aspect of EMT  (94). In another study, the loss of 
p63 in non-transformed and transform squamous cells upregulated genes 
associated with mesenchymal phenotype such as CDH2 (encodes for N-cadherin), 
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WNT5 and ITGA4, and increased migration and invasion. Reasoning that ∆Np63α is 
the most abundant isoform expressed in these cells, the authors proposed ∆Np63 as 
a potential suppressor of invasion and metastasis (95). In line with these findings, 
∆Np63 has been demonstrated to inhibit EMT and cell migration through repressing 
Zeb1 expression via direct transcriptional upregulation of miR-205 in metastatic 
prostate and cervical cancer (30, 96). Interestingly, while depletion of ΔNp63α and β 
isoforms resulted in an EMT phenotype in MCF10A cells, ΔNp63γ exhibited ability to 
upregulate TGFβ and induce EMT (97). More importantly, the loss of ΔNp63 in 
epithelial-like bladder cancer cells promotes EMT and enhance invasion, while the 
induction of ΔNp63 in mesenchymal-like bladder cancer cells triggers MET and 
suppresses invasion (31). This mechanism of action resembles the aforementioned 
spatiotemporal regulation of Twist1 on EMT during metastasis (87), suggesting a 
dynamic regulation of ΔNp63 in cancer metastasis. In a different physiological 
context, downregulation of TAp63, but not ΔNp63, in MDCK cell lines induced EMT 
with increased expression of Twist1, Snail1 and Slug. TAp63 has been shown to  be 
essential for tubulogenesis and cell cyst formation (98). However, a mouse model to 
address the contribution of ΔNp63 in EMT in vivo is still lacking. 
 
1.4 ΔNp63 in cancer progression and metastasis 
1.4.1 Invasion-metastasis cascade 
The metastatic cascade includes a series of events that enable epithelial cells 
in primary tumors to invade and colonize distant tissues. This process consists of 
local invasion into surrounding extracellular matrix, intravasation into the blood 
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stream, survival in circulation, arrest and extravasation into distant tissues, 
adaptation to new environments to form microscopic lesions, and subsequent 
formation of detectable overt metastatic colonies (Figure 7). This multistep process 
is orchestrated by a complex network of signaling pathways not only within tumor 
cells but between tumor cells and surrounding stromal cells (19, 99).  
 
Figure 7: The multistep process of metastatic cascade. During metastatic 
dissemination, migratory tumor cells start to invade surrounding stroma, then 
intravasate into the circulation, subsequently arrested at distant sites, extravasate 
across the endothelium into new organs and proliferate to establish new metastatic 
colonies. (Figure is reproduced from Nieto MA, Huang RY, Jackson RA, Thiery JP. 
Emt: 2016. Cell. 2016;166(1):21-45, with permission from Copyright Clearance 
Center) 
 
Local invasion 
Tumor cells initiate metastatic dissemination process by locally invading 
surrounding stroma. During this first step, cancer cells undergo morphological and 
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genetic changes, and acquire malignant properties to increase mobility and remodel 
extracellular matrix (ECM) in order to move toward the bloodstream (79, 99). There 
are three modes which cancer cells are reported to utilize to leave primary tumors: 
single cell migration, multicellular streaming and collective migration (100, 101). In 
the single cell migration mode, tumor cells tend to lose cell-cell adhesions, become 
more motile and leave primary tumors as individual cells. These single epithelial 
cells can transform into either mesenchymal (invading cells have spindle shape) or 
amoeboid cell types (invading cells have round shape) to invade through local 
microenvironment. In the multicellular streaming mode, individual cells move in a 
multicellular stream or a small strand of cells toward a chemokine gradient. The 
movement of these cells through adjacent stroma is driven by changes in 
cytoskeleton structure of individual cells while the cells still maintain a weak transient 
contact to each other. Collective migration, on the other hand, involves cohesive 
groups or clusters of tumor cells at the invasive front moving together through the 
surrounding stroma. These cells retain high expression of E-cadherin to maintain 
cell-cell adhesion within the invading clusters (79, 100-102). EMT has been shown 
to strongly involve in local invasion of cancer cells, especially in single cell migration 
program. Previously, EMT and collective migration-invasion have been proposed to 
be mutually exclusive due to opposing phenotype observed in invading tumor cells. 
However, recent evidence has raised a question on whether collective invasion is 
actually an alternative program to EMT or function cooperatively with EMT to 
promote cell invasion (79). In fact, breast cancer metastatic colonies have been 
shown to comprise of multiple different clones, indicating that these metastases 
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might arise from clusters of tumor cells instead of one single cell during metastatic 
dissemination (103). These groups of invading cells are led by “leader” cells at the 
invasive front which exhibit mesenchymal traits and secret proteases to degrade 
extracellular matrix in order to pave the way for the “follower” cells in the clusters 
move through the surrounding stroma (79, 104-106). These findings question the 
existence of an intricate interplay between EMT and collective migration-invasion in 
the initial step of metastatic cascade. Further researches are necessary to answer 
whether EMT and collective migration are mutually exclusive, and whether a 
complete block of EMT can prevent collective migration in tumor cells (79). 
 
Intravasation 
Intravasation describes a series of events in which invading tumor cells utilize 
various mechanisms to enter the bloodstream or lymphatic vessels. The 
mechanisms involve transendothelial migration and vessel disruption, which are 
facilitated by molecular changes in invasive tumor cells (99). Various signaling 
pathways have been shown to contribute to disruption of the endothelium by cancer 
cells. Interestingly, transforming growth factor β (TGFβ) has been demonstrated to 
function as a molecular switch between single cell and collective migration. Local 
and transient TGFβ signaling in the primary tumors enhances single cell migration 
and intravasation. However, prolonged TGFβ signaling reduces lung colonization, 
suggesting that a spatiotemporal regulation of TGFβ during metastatic cascade is 
critical for establishment of overt metastases in distant lungs (107). Interestingly, 
increasing evidence has supported the concept of early dissemination of tumor cells 
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(108, 109). In a recent study, early disseminated breast cancer cells from the 
primary tumors have been demonstrated to account for 80% of metastases in a 
Her2-driven breast cancer mouse model (109).  
 
Circulating tumor cells (CTCs) 
When invading tumor cells successfully enter the circulation, they have to 
survive through a variety of stresses in order to travel to distant tissues and seed 
new metastatic colonies. Even though aggressive primary tumors can release plenty 
of cells into the circulation a day, only a few of them eventually develop into overt 
metastases at distant organs, indicating that metastatic dissemination is a very 
inefficient process. Half-life of CTCs in the bloodstream is rather short, ranging from 
a few hours to 2 days (110). Given extreme conditions in the circulation, these CTCs 
have to undergo dramatic molecular changes to adapt and thrive in the new 
environment. They have been shown to develop resistance to anchorage-dependent 
growth and anoikis, and escaping mechanisms from innate immune response (99). 
In addition, a mixed phenotype of epithelial and mesenchymal traits was often found 
in the CTCs, together with increased stem-like properties, further supporting the 
importance of the plastic nature of CTCs in the subsequent dissemination to distant 
sites (85, 104, 111). These CTCs can travel in the bloodstream as either individual 
cells or clusters of cells which are referred as circulating tumor microemboli (CTMs). 
These CTMs can derive either from intravasation of invading cell clusters, or less 
likely from proliferation or aggregation of individual CTCs. However, while traveling 
as clusters might give the CTCs sufficient protection from various attacks in the 
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circulation, which type of CTCs is primarily responsible for metastatic colonization 
remains unclear (79, 112). 
 
Extravasation  
Extravasation starts with the arrest of CTCs or CTMs in blood vessels at 
distant organs. Then, tumor cells migrate across the endothelium via a process 
called transendothelial migration which is similar to intravasation. After successfully 
nesting in the microvasculature of distant tissues, extravasated cancer cells initiate a 
proliferation program to form micro-metastases (79, 112). There are ongoing 
debates on whether the arrest of CTCs at distant sites is organ-specific based on 
evidence that several cancers favor metastatic dissemination to specific organs, for 
example breast cancer patients tend to develop metastasis to the bone, lungs and 
brain. A hypothesis on establishment of a pre-metastatic niche at distant tissues has 
been proposed as a mechanism in which primary tumors release various signals to 
create a more hospitable home for disseminated cancer cells in order to facilitate 
colonization at specific organs (113). 
 
Metastatic colonization 
Metastatic colonization represents the final and most lethal step for tumor 
cells during dissemination process. In fact, majority of disseminated cells fail to form 
overt metastatic colonies at distant organs. These successfully extravasated cells 
may enter a dormancy program in which they retain viability without increase in 
tumor cell mass. The dormant tumor cells either are quiescent or maintain an equal 
  
30  
rate between cell proliferation and apoptosis (112, 114). The dormancy of tumor 
cells may explain tumor recurrence in cancer patients after removal of primary 
tumors. A number of studies have identified regulators of tumor dormancy in order to 
propose potential therapeutic interventions to treat metastatic cancers (115-117). 
Recently, a study has utilized an in vivo shRNA screening strategy to identify MSK1 
as a regulator of metastatic dormancy in ER+ breast cancer (118).  
 
1.4.2 The roles of ΔNp63 in tumor progression and metastasis 
As briefly mentioned in section 1.1.2, given its dominant-negative regulation 
on p53, TAp63 and TAp73, and high expression in multiple squamous cell 
carcinomas and metastases, ΔNp63 has been argued to function as an oncogene in 
human cancers (1, 26, 119). Recent studies have also demonstrated oncogenic 
activities of ΔNp63 in primary tumors of thymic lymphomas and cutaneous 
squamous cell carcinomas (cSCC) in vitro and in vivo. While Venkatanarayan et al. 
identified ΔNp63 as an oncogene in thymic lymphomas in vivo and proposed 
targeting ΔNp63/TAp63/IAPP axis as a potential therapeutic approach to treat p53-
deficient tumors (25), Napoli et al. further explored oncogenic activities of ΔNp63 
through ΔNp63/DCGR8/microRNAs axis and utilized HDAC inhibitors to induce 
tumor regression in both thymic lymphomas and cSCC (27). These findings indicate 
a tumor-promoting effect of ΔNp63 during tumor development. Similar results were 
also observed in breast cancer where overexpression of ΔNp63 in patient tumor-
derived breast cancer sphere cells promotes tumor formation and metastases to the 
lungs in xenograft models. The positive regulation of ΔNp63 on metastasis in this 
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study was shown through PI3K/CD44v6 axis (120). In another study, ΔNp63 was 
shown to promote breast cancer cell migration and invasion via transcriptionally 
regulating oncogene MTSS1 (32).  In keratinocytes expressing HPV16 E6/E7 
proteins, p63 was able to drive cell migration and invasion via modulating Src-FAK 
signaling (121). Adding to the complexity of the pleiotropic roles of ΔNp63 in tumor 
progression and metastasis, several studies have demonstrated ΔNp63 as a 
suppressor of EMT and potentially metastasis as discussed in section 1.3.4. These 
studies also pointed out suppressive activities of ΔNp63 in cancer metastasis 
through other mechanisms. Bergholz et al. demonstrated that ΔNp63α inhibits cell 
invasion and metastasis in breast cancer by negatively regulating Erk signaling via 
direct transcriptional activation of MKP3 (29). More interestingly, Cheung et al. 
provided evidence for essential roles of p63 and K14 in initiating a collective invasion 
program in breast cancer (122). Utilizing an ex vivo 3D tumor organoid model 
derived from luminal B breast cancer mouse model, the authors demonstrated that 
“leader” cells at the invading front strongly expressed basal epithelial markers such 
as K14 and p63, but not EMT-associated factors, including Twist, Slug and Vimentin, 
indicating the initiation of a differentiation program from luminal to basal cells in 
these cells. They further showed that K14-positive leader cells are responsible for 
collective invasion in multiple breast cancer mouse models, including HER2+ luminal 
breast cancer MMTV-Neu model and basal breast cancer C3(1)/Tag model, and in 
primary human breast tumors in vivo as well. Importantly, knockdown of either p63 
or K14 in tumor cells abrogated the collective invasion program. The depletion of 
p63 in organoids resulted in a more dramatic reduction in protrusive tumor cells 
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compared to K14-knockdown. These p63-depleted organoids, however, still partially 
expressed K14, suggesting that p63 might have other K14-independent functions in 
modulating collective invasion. This is not surprising given the fact that K14 has 
been shown to be a direct downstream target of ΔNp63 in basal epidermal cells 
(123, 124). These findings further suggest an intricate involvement of ΔNp63 in 
cancer metastasis. Perhaps, ΔNp63 may function as a molecular switch between the 
two invasion programs given its crucial roles in controlling cell fate and 
differentiation. This is particularly important in the context of both EMT-induced 
single cell invasion and collective invasion have been demonstrated to contribute to 
metastatic dissemination of breast cancer, and whether the two programs are 
mutually exclusive still remains unclear (79, 107).  
In addition, several multiplatform pan-cancer studies have revealed the 
amplification of TP63 gene locus, overexpression of ΔNp63 and the activation of 
TP63/ΔNp63-driven transcriptional network across multiple squamous-like 
carcinomas (125, 126). Hoadley et al. developed an integrated subtype classification 
for 12 different cancers based on a cluster of cluster assignment method. This cross-
platform classification not only defined 13 distinct integrated molecular subtypes, but 
identified genomic- and pathway-based determinants of these subtypes as well. 
Intriguingly, this study demonstrated that lung squamous cell carcinoma (LUSC), 
head and neck squamous cell carcinoma (HNSC), some bladder cell carcinoma 
(BLCA) and  a few lung adenocarcinoma (LUAD) share similar molecular signatures 
and are classified into C2-squamous like subtype. Amplification of TP63, SOX2 and 
PIK3CA, together with loss of CDKN2A, RB and TP53 are often observed in these 
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tumors. Due to previous reports on transcriptional similarities between breast cancer 
(BRCA) and LUSC, the authors then identified common molecular networks between 
two subtypes. More interesting, C2-squamous like tumors showed higher TP63 
(ΔNp63α and TAp63γ) expression and transcriptional activation compared to C4-
BRCA/basal tumors. These features distinguish C2-subtype from others. Potential 
compensatory functions of p63/p73-regulated pathways for impaired p53 have also 
been proposed in HNSC and BRCA, further indicating the significance of 
p53/p63/p73 family transcriptional activities in these cancers (126). Recently, 
Campbell et al. further explored distinguishing molecular features in squamous cell 
carcinomas (SCCs), including genomic, epigenetic, gene and microRNA expression, 
and pathway signatures. Consistent with Hoadley’s study, copy number gain at 
chromosome 3q and overexpression of ΔNp63 in SCCs were also reported in this 
study. Additionally, the authors unveiled distinctive pathways for SCCs that are 
involved in DNA damage, EMT and immune response. Particularly, TP53/63/73-
associated pathways were significantly enriched in SCCs. There was a strong 
expression correlation between microRNA linked to EMT, particularly miR-944, and 
ΔNp63 mRNAs across the pan-SCC dataset, which was later shown to be related to 
differential methylation at transcriptional start sites and other CpG islands of ΔNp63 
(125). Taken together, these integrated pan-cancer analyses reveal the importance 
of p63 signaling pathways in defining molecular subtypes of different cancers. 
Notably, the use of these genomic, epigenetic and expression signatures provides 
additional molecular footprints for different types/subtypes of cancer that can be 
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beneficial for  therapeutic intervention, especially p63-isoform specific targeted 
therapies.  
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Chapter 2: Materials and methods 
Content of this chapter is partly based on the following articles: 
 Hussein Abbas*, Ngoc Bui*, Kimal Rajapakshe, Justin Wong, Preethi Gunaratne, 
Kenneth Y. Tsai, Cristian Coarfa and Elsa R. Flores. Distinct TP63 isoforms 
transcriptional signatures predict tumor progression and clinical outcomes. 
Cancer Research (2018) 78(2), 451–62. *co-first authors  
Copyright permission is not required since Cancer Research journal policy states 
“Authors of articles published in AACR journals are permitted to use their article 
or parts of their article in the following ways without requesting permission from 
the AACR.” 
 Bui NH*, Flores González RE*, Chakravarti D, Coarfa C, Tsai KY and Flores ER. 
ΔNp63 regulates epithelial-mesenchymal transition during wound healing. In 
preparation 
 
2.1 Primary mouse keratinocyte isolation and culture 
Keratinocytes (KCs) were isolated from skin of E18.5 embryos of wild-type 
(WT), ΔNp63-/-, and TAp63-/- mice using Dispase II (Roche) as previously described 
(6). The separated epidermis was then minced and incubated in 0.25% 
Trypsin/EDTA (Corning) for 20 minutes. Cells were then plated on collagen-coated 
flasks (50 μg/ml) (BD Bioscience) in defined K-SFM medium (GIBCO). WT and 
TAp63-/- keratinocytes were cultured in Ham’s F12:DMEM (3:1), and ΔNp63-/- 
keratinocytes were cultured in mouse ES media as previously described (7).  
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2.2 Cell lines and culture conditions 
Normal human epidermal keratinocytes (NHEK) were purchased from Lonza 
and cultured in KGM-Gold media (Lonza). Human mammary epithelial MCF10A, 
human breast cancer MCF10DCIS.com and MCF10CA1D.cl1 cell lines were 
obtained from Barbara Ann Karmanos Cancer Institute (Detroit, MI), and cultured in 
Dulbecco’s modified Eagle’s medium (DMEM)/F12 (1:1) media containing 5% horse 
serum, 1.05 mM CaCl2, 10 μg/ml insulin, 20 ng/nl epidermal growth factor, 500 ng/ml 
hydrocortisone, 10 mM HEPES and 100 μg/ml primocin. Human lung squamous cell 
carcinoma HCC95 cell line was kindly provided by Dr. John Heymachs at UT MD 
Anderson Cancer Center (Houston, TX), and cultured in RPMI 1640 media 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Human 
kidney clear cell carcinoma Caki-1 cell line was purchased from ATCC, and cultured 
in McCoy’s 5A modified media supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin.   
 
2.3 In vitro scratch assay. 
Keratinocytes were plated on 6 well plates on top of J2-3T3 feeder cells. 
Before performing the assay, the feeders were removed using 0.02% EDTA. Then, a 
scratch was made using a 200µl pipette tip. The wound closure was monitored over 
a 24-hour period using time-lapse microscopy. Time-lapse images were taken every 
10 min. For the analysis, individual cells were followed using the time-lapse images 
and their path lengths were quantified and compared. 
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2.4 In vitro Boyden Chamber assay. 
Human and murine keratinocytes were resuspended in 500 μl of media with 
2% FBS (3 × 104 cells/insert) and added to top chambers of the cell migration and 
invasion culture inserts (354578, 354480; BD Biosciences). 750 μl of media with 
20% FBS was added to the bottom chamber. The chamber plates were incubated 
for 24 hours at 37oC. The cell were then fixed and stained with Diff-Quik kit 
(Siemens). Cells from the top chamber were removed using cotton swap. The 
remaining cells were counted with a Zeiss AxioObserver A1 inverted microscope. 
 
2.5 In vivo wound healing assay. 
ΔNp63-conditional knockout mice (ΔNp63fl/fl) were crossed to RosaM/M mice, 
and K14CreER+ mice to generate the ΔNp63fl/fl, RosaM/M, K14CreER+ mice used for the 
in vivo wound healing studies. Mice were anesthetized using inhaled isoflurane and 
a 1 cm wound constrained to the epidermis was made using 250 µl of DXB 
compound (Clearista). Tamoxifen (100 mg/mL) was then applied topically for three 
constitutive days to induce recombination. Control mice were treated with 100% 
ethanol. Mice were euthanized at days 1, 4, and 8 after wounding, and the skin 
section around the wounds were collected. One half of the epithelium was fixed in 
10% formalin, embedded in paraffin and sectioned onto slides. Sections were then 
stained for hematoxylin and eosin (H&E), and the wound sizes were measured and 
analyzed. The other half of the tissue was frozen in OCT medium (Tissue Tek) using 
liquid nitrogen, and sectioned onto slides. Frozen sections were used to assess 
recombination status using fluorescence microscope. 
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2.6 Immunohistochemistry 
Paraffin embedded tissue sections were prepared as described previously 
(20). Sections were incubated with anti-ΔNp63 (619002, Biolegend, 1:1000), Twist1 
(sc-81417, Santa Cruz, 1:100), Lef1 (2230S, Cell Signaling, 1:200), or Ki67 
(ab15580, Abcam, 1:1000) antibody overnight at 4oC in a humid chamber followed 
by incubation with horseradish peroxidase conjugated-secondary antibody in the 
ImmPRESS kit (Vector lab) for 45 minutes at room temperature, then followed by the 
DAB kit (Vector lab). Quantification for ΔNp63-positive cells and signal intensity were 
done using Tissue Studio 4.3 software. Staining score was calculated using the 
following formula: Score =  % positive cells x Average signal intensity. 
 
2.7 Immunofluorescence 
Paraffin embedded tissue sections were prepared as described previously 
(20). Sections were incubated with anti-GFP (ab13970, Abcam, 1:500), Ki67 
(ab15580, Abcam, 1:100), Cytokeratin 5 (ab53121, Abcam, 1:500), E-Cadherin 
(ab76319, Abcam, 1:200), Vimentin (ab92547, Abcam, 1:200) and Cytokeratin 14 
(LS-C22637, LifeSpan Biosciences, 1:500). For secondary antibodies, Alexa Fluor 
568 goat anti-rabbit (703-545-155, Life Technologies, 1:500), FITC goat anti-guinea 
pig (Jackson ImmunoResearch, 1:500), or Alexa Fluor 488 donkey anti-chicken 
(Jackson ImmunoResearch, 1:500) antibodies were used. 
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2.8 qRT-PCR 
Total RNA was isolated from cell pellets using miRNeasy kit (Qiagen). 
Complementary DNA was synthesized from total RNA using SuperScript First-
Strand Synthesis System (Invitrogen). qRT-PCR reactions were performed with the 
7500 Fast real-time PCR System using Power SYBR Green PCR Master Mix (Kapa 
Biosystems) in accordance with the manufacturers’ protocols. The following primers 
were used: human Twist1: 5’-GGAGTCCGCAGTCTTACGAG-3’ (forward) and 5’-
TCTGGAGGACCTGGTAGAGG-3’ (reverse), human Lef1: 5’-
CGGGTACATAATGATGCCAA-3’ (forward) and 5’-
TCACTGTAAGTGATGAGGGGG-3’ (reverse), murine Twist1: 5’-
GCCGGAGACCTAGATGTCATTG-3’ (forward) and 5’-
CACGCCCTGATTCTTGTGAA-3’ (reverse), murine Lef1: 5’-
CCCACACGGACAGTGACCTA-3’ (forward) and 5’-TGGGCTCCTGCTCCTTTCT-3’ 
(reverse). Human GAPDH: 5’-TCTCTGCTCCTCCTGTTC-3’ (forward) and 5’-
GCCCAATACGACCAAATCC-3’ (reverse), and murine GAPDH: 5-
‘TCACCACCATGGAGAAGGC-3’ (forward) and 5’-GCTAAGCAGTTGGTGGTGCA-
3’ (reverse) were used as internal controls. Each sample was run in triplicate. 
Ct values for each gene were calculated and normalized to Ct values for GAPDH. 
 
2.9 miRNA TaqMan assays 
Total RNA were isolated from cell pellets using miRNeasy kit (Qiagen). 500 
ng of total RNA was used to synthesize complementary DNA with the Two-Step 
TaqMan MicroRNA Assay kit (Applied Biosystems) in accordance with the protocol. 
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qRT-PCR was performed with the 7500 Fast real-time PCR System, TaqMan PCR 
master mix (Applied Biosystems), and TaqMan probes (Applied Biosystems) for hsa-
miR-34a-5p (ID: 000426), hsa-miR-98-3p (ID: 472125_mat) and mmu-miR-98* (ID: 
462189_mat), hsa-miR-22-3p (ID:000398), hsa-miR-30a-5p (ID:000417), hsa-miR-
203a-3p (ID: 000507) and hsa-miR-222-3p (ID:002276) . Each sample was run in 
triplicate. Ct values for miRNAs were calculated and normalized to Ct values 
for either human RNU6B (ID: 001093, Applied Biosystems) or murine snoRNA234 
(ID: 001234, Applied Biosystems) 
 
2.10 ChIP assay 
ChIP was performed with nuclear extracts from cell pellets as previously 
described (6, 24). Briefly, cells were grown to 90% confluence. Cells were fixed with 
1% formaldehyde and neutralized by glycine. Samples were sonicated on ice to 
obtain 500-1000bp DNA fragments. 2µg of ΔNp63-specific antibody (sc-8609, Santa 
Cruz), Smad2/3-specific antibody (sc-133098 X, Santa Cruz), Smad2/3 antibody (sc-
133098 X, Santa Cruz) or control IgG (sc-2027, Santa Cruz) was added to each 
sample and incubated overnight at 4oC. Then, protein-DNA complex was 
precipitated using protein A agarose beads/Salmon sperm DNA (Millipore). qRT-
PCR was performed with the following primer sequences specific for p63- or 
Smad2/3-binding sites: human Twist1: 5’-CGCTCTTCTCCTCTGCCC-3’ (forward) 
and 5’- TCTTCCTCGCTGTTGCTCAG-3’ (reverse), human Lef1: 5’-
GCGTTGGTGACGGACTTTTT-3’ (forward) and 5’- TGGAACCCTAATCCCCGAGA-
3’ (reverse), human miR-203a-3p: CAGATCTGGTGGCTGTGTTCT (forward) and 
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ATACCCTAGAGCCCCCTTCAG (reverse), human miR-30a-5p: 
TTGGTTAGGGTTGCTCTTCCC (forward) and AGTCACTGTCAGCAGTTCCC 
(reverse), human miR-22-3p: GAAGATTGGCCTCTGCGGTA (forward) and 
GCCGGCTGTCTGGTTTCTAT (reverse), human miR-222-3p: 
GGCTCTTTTCTCACTTGCGG (forward) and GGTCTACAACATGACAGTCTGGA 
(reverse). Primer sequences for non-specific binding sites were as follows: human 
Twist1 promoter: 5’-AATTCTAGAGGCACCCAGGAG-3’ (forward) and 5’-
GCCCTCTGAATACCAAACTGGA-3’, human Lef1 promoter: 5’-
GCAGAGGCAACAAGGACTGA-3’ (forward) and 5’-TGGCTTCCTCTTGCTCACTG-
3’ (reverse), human miR-203a-3p: CTTGTCTGAGGCTAGGGCTGT (forward) and 
CAGCAACCCAATGACACCCG (reverse), human miR-30a-5p: 
CGGCCCATGTGGAAATGTCT (forward) and TAGAGCCCCCTTCAGCACTT 
(reverse), human miR-22-3p: CCGTATGTTGTAGATGAGGGG (forward) and 
CAGATCTGGTGGCTGTGTTCT (reverse), human miR-222-3p: 
TTCTTAACGGTGTGGGAGGC (forward) and AGAAGTGAACAAAAACTGCCAC 
(reverse). 
 
2.11 Western blot analysis 
50µg of total protein were electrophoresed on 10% SDS-PAGE gel and 
transferred to PVDF membrane as previously described (6, 127). Blots were then 
probed with anti-ΔNp63 (619002, Biolegend, 1:500), E-cadherin (3195, Cell 
Signaling, 1:1000), Vimentin (ab92547, Abcam, 1:1000), Twist1 (sc-81417, Santa 
Cruz, 1:250), Lef1 (2230S, Cell Signaling, 1:1000), Snail (3879S, Cell Signaling, 
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1:1000), Zeb (sc-10572, Santa Cruz, 1:500), Smad2 (sc-101153, Santa Cruz, 
1:500), Smad3 (9523S, Cell Signaling, 1:1000), phospho-Smad2 (ab53100, Abcam, 
1:500),  and phospho-Smad3 (9520S, Cell Signaling, 1:500) overnight at 4oC. 
Horseradish peroxidase conjugated- secondary antibodies against either murine or 
rabbit IgG (Jackson lab) were incubated with the blots for 1 hour at room 
temperature. Actin (A5060, Sigma) or Hsp90 (ab13495, Abcam) was used as 
loading control. Detection was performed using ECL Plus Kit (Amersham) or Licor 
system.  
 
2.12 Lentiviral shRNA infection 
Lentivirus-based vectors (3 μg) overexpressing mmu-miR-34a (SBI), mmu-
miR-98-3p (SBI) or empty vector (as control) were transfected into 293T cells along 
with 3 μg of lentivirus packaging vectors, pCMV-VSVG and pRSV-REV, using X-
tremeGENE HP (Roche) in accordance with the manufacturer’s protocol. After 48 
hours post-transfection, supernatants were collected, filtered and added to ΔNp63-/- 
keratinocytes for 48 hours in the presence of 8 μg/ml Polybrene (Santa Cruz). 
2 μg/ml of purmocyin was added to the media 48 hours after infection for 2 days. 
Cells were then changed to fresh media for further analysis. Infected cells were 
analyzed by miRNA TaqMan assay to determine the level of miRNA overepxression. 
These cells were further analyzed for migration and invasion capacity using Boyden 
chamber assay as described above.  
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2.13 siRNA transfection 
5x105 cells per 60 mm dish were transfected with 40 nM siTwist1-mouse 
(SASI_Mm01_00043025, Sigma) or siLef1-mouse (SASI_Mm01_00158789, Sigma) 
or siLef1-human (SASI_Hs02_00349169 and SASI_Hs01_00151600, Sigma) or 
si∆Np63 (Sense: CAGCAGCAUUGAUCAAUCUUA, Antisense: 
UAAGAUUGAUCAAUGCUGCUG) using Lipofectamine RNAi Max (Invitrogen) 
according to manufacturer’s protocol. The cells were collected 48 hours post-
transfection for further analysis. Transfected cells were analyzed by western blot to 
determine knockdown efficiency. These cells were further analyzed for migration and 
invasion capacity using a Boyden chamber assay as described above, or for cell 
proliferation and anchorage-independent colony formation.   
 
2.14 MicroRNA mimics and inhibitors transfection 
5x105 cells per 60 mm dish were transfected with 40 nM microRNA inhibitors 
(ThermoFisher) or 6 nM microRNA mimics (ThermoFisher) using Lipofectamine 
RNAi Max (Invitrogen) according to manufacturer’s protocol. The cells were 
collected 48 hours post-transfection for further analysis. The microRNA inhibitors 
used to target microRNAs are as followed: miR-203a-3p (MH10152), miR-30a-5p 
(MH11062), miR-22-3p (MH10203), miR-222-3p (MH11376) and negative control 
(4464077) (ThermoFisher). The microRNA mimics purchased from ThermoFisher 
are miR-10b-5p (MC11108), miR-21-5p (MC10206), miR-22-3p (MC10203), miR-
30a-5p (MC11062), miR-141-3p (MC10860), miR-181a-5p (MC10421), miR-200a-3p 
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(MC10991), miR-203a-3p (MC10152), miR-222-3p (MC11376) and negative control 
mimics (4464058).  
 
2.15 Plasmid transfection 
0.5×106 cells were plated in 6-cm dishes. 1µg of plasmids was transfected 
into the cells using X-tremeGENE HP DNA transfection reagent (Sigma) according 
to manufacturer’s protocol. The cells were collected 48 hours post-transfection for 
further analysis. Transfected cells were analyzed by western blot to determine 
overexpression efficiency. These cells were further analyzed for cell proliferation and 
anchorage-independent colony formation.  pcDNA3.1-DYK-Lef1 and pcDNA3.1-
DYK-empty plasmids were obtained from Genscript. ΔNp63α ORF was cloned into 
pcDNA3.1-Myc-empty plasmid. 
 
2.16 Cell proliferation assay 
0.5x104 cells were plated in 6 replicates in 96 well-plate subsequent to 
siRNA/DNA transfection overnight. Cell were then incubated with 10 nM EdU (5’-
ethynyl-2’-deoxyuridine) for either 1.5 hours (MCF10CA1D) or 4 hours (HCC95) or 
48 hours (Caki-1), and stained using the Click-iT EdU microplate assay (Invitrogen) 
according to manufacturer’s protocol. Images were captured using an Olympus IX83 
inverted fluorescent microscope. Quantification of the percent of cell proliferation 
was obtained using Celigo and Incucyte instruments. 
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2.17 Growth curve 
0.2x104 cells per well were plated onto 96-well plates. The plates were read 
with the IncuCyte (Essence Bioscience) every 6 hours for 72 hours. Cell confluency 
or density was measured using IncyCyte Zoom software.  
 
2.18 Soft agar assay 
5x104 cells were seeded in 1 ml of 0.3% top agar layer in six-well plates 
subsequent to siRNA/DNA transfection. The base layer was composed of 1.5 ml of 
0.6% agar in culture media. Plates were allowed to solidify at room temperature, 
then 1.5 ml of culture media was added to each well. Plates were incubated at 37 
°C, and the media was changed every 3 days for 14 days. Colonies were then 
stained with 0.005% crystal violet for 1 hour. The number of colonies per 10X field 
was counted using Olympus IX83 and Zeiss Observer.Z1 inverted fluorescent 
microscopes.  
 
2.19 Luciferase reporter assay 
3’UTR of TP63 gene was cloned into pLightSwitch backbone (pLightSwitch-
3’UTR-TP63) (Activemotif). One day before transfection, 1x104 cells per well were 
plated onto white 96-well plates. Next day, 100 ng empty vector or pLightSwitch-
3’UTR-TP63 vector was transfected together with 20 nM microRNA mimics into the 
cells using Lipofectamine 2000. 48 hours post-transfection, the plates were kept at   
-80oC overnight. On the day of the assay, the plates were thawed at RT for at least 
45 minutes prior to assaying luciferase activity. Then, 100 µl of LightSwitch assay 
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solution (Activemotif) was added to each well, incubate for 30 minutes at RT in the 
dark. Each well was read for 2 seconds in a plate luminometer (Promega).  
 
2.20 Site-directed mutagenesis  
Mutated versions of the 3’UTR of TP63 was generated using Q5 Site-directed 
mutagenesis kit (New England Biolabs) following manufacturer’s protocol. Primers 
with substitution mutations of the seed sequences of the microRNAs were designed 
using primer design software NEBaseChanger (New England Biolabs). The following 
primers were used to generate mutant versions of the 3’UTR of TP63 for each 
microRNA tested: miR-22-3p: CAACAAGCATcgtcgaTTGCAAACCCATTAAGGGG 
(Forward) and CAGAAGTTTACAGTGCTTATTAC (Reverse), miR-30a-5p: 
atgCTTTCTCTCTCTAAGGTTTACAATAG (Forward) and 
ttgtAGCCTCTACATGCAGAGT (Reverse), miR-203a-3p: 
aagTTCTAGTGATGATGGTTC (Forward) and 
tacaCAGTAATATAAAATATACCAACAC (Reverse), miR-222-3p: 
CTTGCAGAACacatcgTGCCATGGCTAGGTAG (Forward) and 
CTATAGTTTTGAAGGCTTAAAG (Reverse).  
 
2.21 In vivo mammary fat pad injection 
2x106 cells mixed 1:1 ratio with growth factor reduced matrigel (BD 
Biosciences) were injected into the left and right mammary fat pads of nude mice. 
After two weeks post-injection when the tumors became palpable, the mice were fed 
with either control diet or doxycycline (dox) diet (200 mg/ kg, Bio-Serv) to induce 
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expression of the sh∆Np63. At the end of the experiments, all the mice were 
euthanized and performed necropsy to collect tumors and internal organs for further 
analysis. Tumor sizes (length and width) were measured using a caliper.  Tumor 
volume was calculated using the following formula: Tumor volume = 
1/2(length × width2) 
 
2.22 In vivo tail vein injection 
Cells were trypsinized and washed with HBSS (without Mg2+ and Ca2+), 
filtered through 70 µM cell strainers and resuspended in HBSS (without Mg2+ and 
Ca2+). 5x105 cells were injected into nude mice via tail vein. The mice were fed with 
either control diet or dox diet (200 mg/ kg, Bio-Serv) one day before injection, and 
continued with the diet for 8 weeks. Then, the mice were euthanized and the lungs 
were collected for further analysis.   
2.23 Isolation of RPF-positive cells in the lungs 
The cells were infected with Firefly luciferase-T2A-RFP-Puro (Biosettia) to 
make stable cell line expressing RFP, then injected to nude mice via tail vein. The 
mice were fed with either control diet or dox diet one day before injection. 48 hours 
post-injection, the mice were euthanized, and the lungs were collected and 
dissociated as previously described (128, 129). In brief, the lungs were perfused with 
cold PBS until they were clear of blood. 2 mL of dispase (50 U/mL, BD Bioscience) 
was injected into the trachea just until the lungs inflated. Then, 0.5 mL of 1 % low-
melting agarose was injected to the lungs, cover chest cavity with crushed ice for 2 
minutes to set agarose. The lungs were dissected out and placed in cold PBS on 
  
49  
ice. After that, the lungs were minced into small pieces in PBS, and 
collagenase/dispase (100 mg/mL, Roche) was added to the tissue homogenates. 
After 45 minutes rotating at 37oC, digested tissue was treated with 1 % DNase 
(Sigma) and lysed of red blood cells (RBC) using RBC lysis buffer (BioLegends). 
Cell pellets were then used for cell sorting to analyze population of RFP-positive 
cells.  
 
2.24 miRNA-mRNA functional pair analysis 
The functional pair analysis was performed for downregulated miRNAs and 
upregulated mRNAs in the miRNA-Seq and RNA-Seq data from wild type and 
ΔNp63-/- keratinocytes (7). Predicted targets of miRNAs enriched in the upregulated 
genes were determined using the TargetScan and the exact Fisher’s test (q < 0.05).  
 
2.25 Bioinformatics analysis 
The primary and processed data for 9578 tumor and 730 normal samples 
were downloaded from The Cancer Genome Atlas website between July 2014 and 
February 2015. We aligned all TCGA sequencing data to Genome Reference 
Consortium Human Reference 38 (hg38) in order to identify all genes and TP63 
isoforms (α, β, γ for TAp63 and ΔNp63). TAp63 signatures were derived from 
epidermal cells P1 TAp63-/- and wild type mice at embryonic day 18.5 (6). For ΔNp63 
murine gene signature, we used previously published transcriptome profiles (7). For 
putative tumor suppressor role of the TAp63 or ΔNp63, we identified genes that 
were significantly changing and in the same direction in both TAp63-/- (or ΔNp63-/-) 
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and the corresponding tumor signature. For oncogenic roles, an inverse approach 
was taken. PCSS was identified separately for each gene signature and for each 
role (eg. tumor suppressor or oncogene) using association of gene scores and 
survival that conforms with the predicted function. The highest-ranking genes were 
then combined to establish a robust PCSS. Z-scores were used for all activity 
scoring then ranked by the highest and lowest 25th percentile quartiles. We utilized 
BP, KEGG and Reactome compendiums for pathway analysis.  
2.26 NanoString microRNA analysis to identify differential expressed 
microRNAs 
2x105 MCF10DCIS cells were treated with TGFβ1 (10 ng/mL) for 72 hours, 
then collected for total RNA using miRNaesy Kit (Qiagen) following manufacturer’s 
protocol. Experiments were done in quadruplicate. Then, RNA samples were run in 
the NanoString human microRNA panel (NanoString) following manufacturer’s 
protocol. Briefly, annealing master mix was prepared and added to each tube of a 12 
x 0.2 mL strip tube. RNA was then added to each tube. Samples were annealed, 
ligated and purified in a thermocycler following the kit’s protocol. Next, samples were 
hybridized with Capture probeset for 12 hours followed by post-hybridization 
processing with the nCounter Analysis System.  
Raw array data files (RCC) and miRNA panel file (RLF) were read using 
nSolver 3.0 software (NanoString). Data Quality metrics was also generated by this 
software with the default parameters (Field of view (FOV) <75, Binding density is 
between 0.05 and 2.25, Positive control linearity R2 > 0.95, 0.5fM positive control 
limit of detection < 2 STDEV).  Comparison of normalization methods for 
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NanostringDiff (130), Housekeeping genes and NanoStringNorm (131) were made. 
Raw NanoString counts were normalized using NanostringDiff package. Normalized 
data were log2 transformed. Limma package (132) was used for gene differential 
analysis between two groups. Significant genes were selected as adjusted p value 
<0.05 and fold change greater than 2. Heatmaps of the significant genes were 
generated by gplots package of bioconductor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
52  
 
 
 
 
 
 
 
 
3. CHAPTER 3: ∆Np63 REGULATES EPITHELIAL TO MESENCHYMAL 
TRANSITION DURING WOUND HEALING VIA TRANSCRIPTION FACTORS 
TWIST1 AND LEF1 
 
 
 
 
 
 
 
 
 
 
 
  
53  
Chapter 3: ∆Np63 regulates epithelial to mesenchymal transition during wound 
healing via transcription factors Twist1 and Lef1 
Content of this chapter is partly based on the following manuscript: 
 Bui NH*, Flores González RE*, Chakravarti D, Coarfa C, Tsai KY and Flores ER. 
ΔNp63 regulates epithelial-mesenchymal transition during wound healing. In 
preparation 
 
3.1 Introduction and rationale 
Given the crucial roles of ΔNp63 in maintaining epithelial structure and 
homeostasis and its high expression in basal keratinocytes, a major component 
participating in wound repair, ΔNp63 may play an important role during wound 
healing process. Therefore, I aimed to investigate whether the loss of ΔNp63 in 
basal epidermal cells could have any significant impact on normal wound repair by 
utilizing a conditional ΔNp63-knockout mouse model and an in vivo cutaneous 
wound healing model. 
 
3.2 Results 
3.2.1 The loss of ∆Np63 induces EMT in mouse and human keratinocytes in 
vitro 
Keratinocytes isolated from ∆Np63-/- mice are reported to be highly 
proliferative and express several pluripotency-associated factors including Oct4, 
Sox2 and Nanog (7). Strikingly, these ∆Np63-deficient epidermal cells exhibited  
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Figure 8: Depletion of ΔNp63 promotes an epithelial to mesenchymal 
transition in mouse and human keratinocytes in vitro. A-D, cell morphology of 
Wild-type (WT) (A) and ΔNp63-/- mouse keratinocytes (KCs) (B), and WT (C) and 
ΔNp63 knocked-down normal human epidermal keratinocytes (NHEK) (D). E-F, 
western blot analysis for expression of EMT-related factors in WT and ΔNp63-/- KCs 
derived from three independent embryos (E) and WT and ΔNp63 knocked-down 
NHEK (NHEK-shΔNp63) (F) using the indicated antibodies. Actin and Hsp90 were 
used as loading controls.  
 
 
 
 
 
 
 
 
  
55  
dramatic change in morphology from epithelial-like to elongated spindle-like shape 
(Figure 8A-B), suggesting a transition from epithelial to mesenchymal state. The 
same morphological change was observed in normal human epidermal 
keratinocytes (NHEKs) when ΔNp63 was knocked using shRNA (Figure 8C-D). To 
ask if these morphological changes were related to EMT, several hallmarks of EMT 
were examined. Both mouse and human ΔNp63-depleted keratinocytes showed 
decreased expression in E-cadherin, an epithelial cell adherens junction protein, 
while level of vimentin, a marker for mesenchymal cells, was upregulated. In 
addition, several EMT-associated transcription factors, including Twist1, Snail1, Lef1 
and Zeb1, were also elevated in both ∆Np63-/- KCs and NHEK-shΔNp63 cells 
(Figure 8E-F). EMT is often accompanied with increase in cell motility (47). 
Therefore, I next asked if the ablation of ΔNp63 led to increased cell migration and 
invasion in both KCs and NHEKs in vitro. Indeed, ∆Np63-/- KCs showed significant 
increase in cell movement toward scratch sites compared to WT and TAp63-/- KCs. 
Especially, ∆Np63-/- KCs demonstrated a movement pattern of individual cells with 
loose cell-cell contact while TAp63-/- KCs moved toward wounded sites as a whole 
sheet of cells (Figure 9A-B), further confirming the induction of EMT upon ∆Np63 
depletion. Moreover, ∆Np63-/- KCs also exhibited higher migratory and invasive 
capabilities compared to WT KCs (Figure 9C-D). Similar increase was observed 
when ∆Np63 was knocked down in NHEKs (Figure 9E-F). Taken together, these 
data indicate an induction of EMT upon depletion of ΔNp63 in epidermal cells.  
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Figure 9: Depletion of ΔNp63 increases cell migration and invasion in mouse 
and human keratinocytes in vitro. A-B, in vitro scratch assay using WT, ΔNp63-/-, 
and TAp63-/- KCs. Representative images for time points for 0, 8 and 24 hours (A) 
and measurement of distance traveled by WT, ΔNp63-/-, and TAp63-/- KCs (B), 
Asterisks indicate statistical significance, p ≤0.0003 versus WT KCs. C-D, Boyden 
chamber assay for migration (C) and invasion (D) capacity of WT, ΔNp63-/-, and 
TAp63-/- KCs. E-F, Boyden chamber assay for migration (E) and invasion (F) 
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capacity of WT NHEK and NHEK-shΔNp63, Asterisks indicate statistical 
significance, p < 0.0001 versus WT NHEK.  
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3.2.2 ΔNp63 depletion delays wound healing process in vivo 
Wound healing is a normal physiological process to re-epithelialize injured 
skin areas. Basal keratinocytes play crucial roles during the re-epithelialization (73). 
Given the important roles of ΔNp63 in biological functions of keratinocytes, we asked 
if ΔNp63 contributes to regulation of wound repair. To further characterize the 
contribution of ΔNp63 in wound healing process, an in vivo cutaneous wound 
healing model was developed to utilize a ΔNp63-conditional knockout mouse model 
(ΔNp63fl/fl) generated in the Flores lab (7). These mice were crossed to RosaM/M 
mice and K14CreER+ mice to generate ΔNp63fl/fl, RosaM/M, K14CreER+ mice. The triple 
mutant mice expressed a tdTomato lox-stop-lox (LSL) GFP reporter cassette 
inserted into ROSA26 locus, resulting in continuous expression of RFP red 
fluorescence. Upon the expression of Cre recombinase in the presence of tamoxifen 
(TAM), GFP is expressed with green fluorescence indicating successful 
recombination. Since Cre recombinase can only be induced in K14-expressing cells, 
the recombination is restricted to basal epidermal keratinocytes upon tamoxifen 
treatment.  
In this in vivo cutaneous wound healing model, 1 cm- wounds were generated 
using the proprietary compound DXB, which only removes the epidermis of the skin 
while leaving the dermis intact. This approach specifically examined roles of ΔNp63 
in epidermal cells during re-epithelization.  After wounding, tamoxifen (ΔNp63Δ/Δ, 
R∆/∆, K14CreER+ or ΔNp63Δ/Δ for short) and ethanol (ΔNp63fl/fl, RM/M, K14CreER+ or 
ΔNp63fl/fl for short) were applied to the wound sites. The skins were collected after 1, 
4, and 8 days post-wounding (Figure 10A). The recombination was confirmed by the 
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expression of GFP at day 4 post-wounding in tamoxifen-treated group (ΔNp63Δ/Δ), 
but not in control ethanol-treated group (ΔNp63fl/fl) (Figure 10B). Skin samples were 
processed and stained with hematoxylin and eosin (H&E). Then, wound size was 
measured at each time point. The results showed that the ΔNp63Δ/Δ mice 
demonstrated defects in wound healing compared to the control group. While the 
control mice had completely re-epithelialized the wound sites after 4 days post-
wounding, the ΔNp63Δ/Δ mice still maintained unhealed wounds even after 8 days 
post-wounding (Figure 10C-D). A staining of K5, a cytokeratin marker for basal cells 
and GFP in the skin sections confirmed the delay in re-establishing the epithelial 
sheets at the wound sites on ΔNp63Δ/Δ mice (Figure 10E), suggesting that the loss of 
ΔNp63 in basal keratinocytes prevents wound repair process.  
Next, the skin sections were stained for K14, another marker for basal cells, 
and Ki67, a marker for cell proliferation, to determine if the ablation of ΔNp63 in 
keratinocytes reduced cell proliferation which potentially contributed to the delay in 
wound healing. Surprisingly, ΔNp63Δ/Δ keratinocytes showed no significant 
difference in proliferation compared to ΔNp63fl/fl cells at day 1 post-wounding. 
However, while ΔNp63fl/fl keratinocytes significantly reduced proliferative capacity 
after 4 and 8 days post-wounding when the re-epithelialization process was 
completed, ΔNp63Δ/Δ keratinocytes maintained high proliferation rate even after 8 
days post-wounding when the wounds still remained open (Figure 11A-B). These 
data suggest that ΔNp63 depletion in basal keratinocytes delays wound healing 
process, but not due to defects in cell proliferation.  
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Figure 10: ΔNp63 loss delays epithelial wound healing in vivo. A, Experimental 
design for in vivo cutaneous wound healing model. ΔNp63fl/fl, RosaM/M, K14CreER+ 
mice were treated topically with DXB compound to create 1-cm wounds and induced 
recombination constrained to the epidermis by tamoxifen for 3 consecutive days. 
Wound sites were assessed on days 1, 4, and 8 post-wounding. B, Representative 
fluorescent images of frozen skin sections from ΔNp63fl/fl, RM/M, K14CreER+ (Left) and  
ΔNp63Δ/Δ, R∆/∆, K14CreER+ (Right) for TdTomato (Red), GFP (Green) and Nuclear 
(Blue). C, H&E sections of ΔNp63fl/fl, RM/M, K14CreER+ and ΔNp63Δ/Δ, R∆/∆, K14CreER+ 
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skin collected on days 1, 4, and 8 after wounding. The dotted line marks the 
epidermis-dermis border, and the box marks the wound site. D, Quantification of 
wound size on days 1, 4, and 8 post-wounding. n = 3, Asterisks indicate statistical 
significance, p < 0.05 versus ΔNp63fl/fl, RM/M, K14CreER+ mice. E, Double 
immunofluorescence staining of ΔNp63fl/fl, RM/M, K14CreER+ and ΔNp63Δ/Δ, R∆/∆, 
K14CreER+ skin sections on days 1, 4, and 8 after wounding for K5 (red) and GFP 
(green). Figure 9A-D was prepared by Ramon Flores González, M.D., Ph.D.  
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Figure 11: ΔNp63-deficient basal keratinocytes maintain high proliferative 
capacity during wound healing. A, Double immunofluorescence staining of 
ΔNp63fl/fl and ΔNp63Δ/Δ wound sites on days 1, 4, and 8 after wounding for K14 
(green) and Ki67 (red). B, Quantification of Ki67-positive cells on days 1, 4, and 8 
post-wounding. n = 3, Asterisks indicate statistical significance, p< 0.0002 versus 
ΔNp63fl/fl   
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3.2.3 The depletion of ΔNp63 induces an EMT during wound healing process 
in vivo 
Since ΔNp63-deficient keratinocytes do not exhibit defects in cell proliferation, 
another mechanism might account for the impaired re-epithelialization process 
during wound repair. Keratinocytes at the migratory front have been shown to 
undergo a “partial EMT” in which epidermal cells gain motility while maintaining 
loose cell-cell contact necessary for re-epithelialization of wounded sites (47, 74). 
The fact that a “partial” EMT is a key feature during wound healing prompted a 
question on whether a complete “irreversible” EMT induced by depletion of ΔNp63 
during wound healing would interfere with the process. In order to address this 
question, skin sections from both ΔNp63fl/fl and ΔNp63Δ/Δ mice were stained for E-
cadherin and Vimentin. Similar to in vitro data, the loss of ΔNp63 indicated by GFP 
expression in epidermal cells in ΔNp63Δ/Δ mice decreased expression of E-cadherin 
in both day 4 and 8 after wounding (Figure 12A). Interestingly, while Vimentin was 
induced in skin samples from both ΔNp63fl/fl and ΔNp63Δ/Δ mice at day 1 post-
wounding, only ΔNp63Δ/Δ epidermal cells maintained expression of Vimentin until 8 
days after wound induction (Figure 12B).  This suggests that ΔNp63-depleted 
epidermal cells undergo a more complete EMT, further transitioning into a 
mesenchymal state. 
To further confirm the induction of an EMT upon the depletion of ΔNp63 
during wound repair process, skin sections from both ΔNp63fl/fl and ΔNp63Δ/Δ mice 
were stained for known EMT-related transcription factors, Twist1 and Lef1. The 
results demonstrated that Twist1 and Lef1 were up-regulated epidermal cells from 
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ΔNp63Δ/Δ mice since day 4 post-wounding, while cells from ΔNp63fl/fl mice showed 
undetectable expression of these two transcription factors even at day 1 after 
wounding (Figure 13A-B). In summary, these data show that the loss of ΔNp63 in 
epidermal cells promotes an “irreversible” EMT via activation of transcription factors 
Twist1 and Lef1, which prevents the wound healing process. 
 
3.2.4 ΔNp63 modulates EMT in epidermal cells via regulating expression of 
Twist1 and Lef1 
To identify underlying mechanisms in which ΔNp63 regulates EMT in basal 
keratinocytes, ΔNp63-/- cells were knocked down of Twist1 and Lef1 using siRNAs, 
and assessed for migration and invasion capacity. Western blot data confirmed 
successful down-regulation of Twist1 and Lef1 (Figure 14A). Similar to data obtained 
in previous experiments, ΔNp63-/- KCs transfected with non-targeting siRNA control 
(NT) showed significant increase in both migration and invasion compared to WT 
KCs. The knockdown of either Twist1 or Lef1 in ΔNp63-/- KCs rescued the 
phenotype, decreasing number of migrating and invading cells through the 
membranes (Figure 14B-C). However, the rescue effects were partial compared to 
WT KCs. This indicates that Twist1 and Lef1 partially contribute to the increased 
invasiveness of basal epidermal cells upon depletion of ΔNp63. 
As shown in Figure 8B, protein levels of both Twist1 and Lef1 were up-
regulated in ΔNp63-/- KCs. In addition, a significant induction of Twist1 and Lef1 at 
mRNA level was observed in both human and mouse keratinocytes when ΔNp63  
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Figure 12: ΔNp63-depleted keratinocytes display a mesenchymal phenotype 
during wound healing in vivo. A-B, Double immunofluorescence staining of 
ΔNp63fl/fl and ΔNp63Δ/Δ wound sites on days 1, 4, and 8 post-wounding for E-
cadherin (red) and GFP (green) (A), or Vimentin (red) and GFP (green) (B) 
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Figure 13: ΔNp63-depleted keratinocytes undergo a complete EMT during 
wound healing in vivo. A-B, Immunohistochemical staining of ΔNp63fl/fl and 
ΔNp63Δ/Δ skin sections at day 1, 4, and 8 after wounding for Twist1 (A) and Lef1 (B)     
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was depleted (Figure 14D-E), suggesting Twist1 and Lef1 might function 
downstream of ΔNp63 in regulating EMT. To decide if there was a direct 
transcriptional repression of ΔNp63 on Twist1 and Lef1 expression, chromatin 
immunoprecipitation of ΔNp63 on the promoters of Twist1 and Lef1 was performed 
in WT and ΔNp63-/- KCs. However, the results failed to demonstrate enrichment of 
ΔNp63 on Twist1 and Lef1 promoters (Figure 14F-G), indicating no direct binding 
was observed. Taken together, these findings identified Twist1 and Lef1 as indirect 
downstream targets of ΔNp63 in regulating EMT. Other ΔNp63-mediated pathways 
might be involved in controlling expression of these two transcription factors.           
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Figure 14: ΔNp63 modulates EMT via regulating expression of Twist1 and 
Lef1. A, Western blot analysis for knockdown efficiency of either Twist1 or Lef1 in 
ΔNp63-/- KCs. B-C, Boyden chamber assay for migration (B) and invasion (C) of WT 
KCs and ΔNp63-/- KCs transfected with either siTwist1 or siLef1. Asterisks indicate 
statistical significance, p ≤ 0.0006 versus WT KCs. D-E, qRT-PCR of human and 
murine Twist1 mRNA (D) and Lef1 mRNA (E) in NHEK-WT, NHEK-shΔNp63, WT 
KCs and ΔNp63-/- KCs. Asterisks indicate statistical significance, p < 0.0005 versus 
NHEK-WT or WT KCs. F-G, qRT-PCR of chromatin immunoprecipitation of ΔNp63 
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binding to promoters of human Twist1 (F) and Lef1 (G) genes in NHEK-WT and 
NHEK-shΔNp63. NSBS, non-specific binding sites. 
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3.2.5 miR-98-3p and miR-34a-5p modulate EMT in keratinocytes via Twist1 
and Lef1  
Since Twist1 and Lef1 are not direct targets of ΔNp63 during EMT induction, 
other ΔNp63-mediated pathways may account for the regulation of ΔNp63 on these 
two factors at protein level. MicroRNAs have been intensively shown to play 
essential roles in post-transcriptional regulation of EMT-associated transcription 
factors, including Twist1 and Lef1 (60, 61). Moreover, ΔNp63 is involved in 
microRNA biogenesis machinery through direct transcriptional activation of DGCR8 
(7), suggesting that ΔNp63 might regulate Twist1 and Lef1 expression through 
microRNAs. Utilizing published RNA and microRNA profiles of WT and ΔNp63-/- KCs 
from the Flores lab (7), a microRNA-mRNA functional pair analysis was performed to 
identify up-regulated microRNAs that potentially regulate Twist1 and Lef1 expression 
upon ΔNp63 depletion. While the analysis identified several candidate microRNAs 
regulating Zeb1/2, only miR-98-3p (miR-98) and miR-34a-5p (miR-34a) were linked 
to Twist1 and Lef1, respectively (Figure 15A). Next, expression validation results 
showed that both miR-98 and miR-34a were down-regulated upon the ablation of 
ΔNp63 in both mouse and human keratinocytes (Figure 15B-C). Furthermore, the 
overexpression of miR-98 or miR-34a in ΔNp63-/- KCs reduced expression of Twist1 
or Lef1, respectively (Figure 16A-D). The reduction in Twist1 and Lef1 level in 
ΔNp63-/- KCs led to significant decrease in migration and invasion capacity of 
ΔNp63-/- KCs compared to WT KCs (Figure 16E-F). In summary, ΔNp63 represses 
expression of Twist1 and Lef1 via miR-98 and miR-34a respectively, to prevent EMT 
in epidermal cells.  
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Overall, these data elucidate inhibitory effects of ΔNp63 on EMT in epidermal 
cells through regulating Twist1 and Lef1. Thus, the depletion of ΔNp63 in basal 
keratinocytes during wound healing elicits an irreversible EMT, which in turn delays 
wound repair process in vivo. 
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Figure 15: miR-98-3p and miR-34a inhibit expression of Twist1 and Lef1, 
respectively in keratinocytes. A, MicroRNA-RNA pair analysis for genes 
associated with EMT upon the depletion of ΔNp63 in KCs. B-C, Taqman qRT-PCR 
of miR-98-3p (miR-98) (B) and miR-34a-5p (miR-34a) (C) in NHEK-WT, NHEK-
shΔNp63, WT KCs and ΔNp63-/- KCs. Asterisks indicate statistical significance, p ≤ 
0.0001 versu NHEK-WT or ΔNp63-/- KCs.      
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Figure 16: ΔNp63 represses cell migration and invasion via miR-98/Twist1 and 
miR-34a/Lef1 axes. A-B, Taqman qRT-PCR of miR-98 (D) and miR-34a (E) in 
ΔNp63-/- KCs overexpressing either miR-98 (D) or miR-34a (E). Asterisks indicate 
statistical significance, p < 0.0001 versus empty vector (EV). C-D, Western blot 
analysis of Twist1 (F) and Lef1 (G) expression levels in ΔNp63-/- KCs 
overexpressing either miR-98 (F) or miR-34a (G). E-F, Boyden chamber assay for 
migration (H) and invasion (I) assay of WT KCs and ΔNp63-/- KCs infected with 
either miR-98, miR-34a, or empty vector. Asterisks indicate statistical significance, p 
< 0.0006 versus empty vector (EV). 
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Chapter 4: Pleiotropic roles of ∆Np63 in tumor development and progression 
Content of this chapter is based on the following article: 
 Hussein Abbas*, Ngoc Bui*, Kimal Rajapakshe, Justin Wong, Preethi Gunaratne, 
Kenneth Y. Tsai, Cristian Coarfa and Elsa R. Flores. Distinct TP63 isoforms 
transcriptional signatures predict tumor progression and clinical outcomes. 
Cancer Research (2018) 78(2), 451–62. *co-first authors  
Copyright permission is not required since Cancer Research journal policy states 
“Authors of articles published in AACR journals are permitted to use their article 
or parts of their article in the following ways without requesting permission from 
the AACR.” 
 
4.1 Introduction and rationale 
Even though the contributions of p63 have been described in multiple 
cancers, its transcriptional roles in tumor development and progression are 
perplexing due to the existence of several isoforms and their variable expression in 
different types of tissues, as well as their complex interaction with each other and 
with p53 (1, 20, 22, 25, 27). While TAp63 has been demonstrated as a suppressor of 
tumorigenesis and metastasis in various cancers, functions of ΔNp63 in cancers 
remain controversial. Complex roles of ΔNp63 have been observed in different types 
and stages of cancers (15, 22, 25, 27, 120, 133, 134). Therefore, a global approach 
is essential to provide a comprehensive insight into tissue-specific roles of the genes 
regulated by ΔNp63 in cancer development and progression, which may ultimately 
explain ΔNp63-associated opposing phenotypes in different cancers. By applying an 
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integrative model for TAp63 and ΔNp63 signatures from mice into The Cancer 
Genome Atlas (TCGA) derived signatures, we aimed to decipher tissue-specific 
transcriptional activities of TAp63 and ΔNp63 across multiple cancers in order to 
propose these signatures as potential prediction tools to further stratifying patients 
into groups that can benefit from p63-isoform specific targeted therapy (25, 27). 
 
4.2 Results 
4.2.1 Gene Set Enrichment Analysis (GSEA) and signature activity reveal 
pleiotropic roles of TAp63 and ΔNp63 in tumor development and 
progression 
TAp63 and ΔNp63 RNA signatures were generated from primary TAp63-/- 
KCs (135) and ΔNp63-/- KCs (7). Then, these signatures were used to analyze for 
p63 isoform-specific transcriptomes across multiple cancers in TCGA database. 
Since different biological processes and pathways are activated during cancer 
development and progression, distinct RNA signatures for tumor development and 
progression were derived by comparing the expression profile of tumors to normal 
tissues and expression profile of high stage/grade tumors to low stage/grade tumors, 
respectively (135).  Next, the TAp63- and ΔNp63-specific transcriptomes were 
characterized for enrichment in 17 tumor development and 27 tumor progression 
signatures by employing the GSEA algorithm (136). Identification of putative tumor 
suppressor and oncogene activities of p63 isoforms in cancer development and 
progression was based on significance, directionality, and enrichment concordance. 
Specifically, when both upregulated and downregulated tumor-associated signature 
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genes are significantly enriched in concordant direction (positive normalized 
enrichment scores (NES) for upregulated genes, and negative NES for 
downregulated genes) with TAp63-/- or ΔNp63-/- signatures, this suggests a 
concordance with the TAp63 or ΔNp63-deficient genotypes, thus a potential tumor 
suppressor activity. Alternatively, discordant enrichment in TAp63-/- or ΔNp63-/- 
signatures suggests a predominant wildtype phenotype, and hence a potentially 
corresponding oncogenic activity. Based on this approach, we then identified p63 
isoforms-derived signatures to measure corresponding transcriptional activity among 
patients and across stages, and to assess for survival (Figure 17A). 
Interestingly, TAp63 consistently exhibited a tumor suppressor pattern in 13 
cancer development signatures and 5 progression signatures, while ΔNp63 
exhibited a pleiotropic role in tumorigenesis and cancer progression: an oncogenic 
pattern in 7 development and 1 progression signatures, and a tumor suppressive 
pattern in 3 development and  5 progression signatures (q<0.0001) (Figure 17B). 
 
4.2.2 TAp63 and ΔNp63 signatures predict patient survival   
To enable pan-cancer clinical assessment applications informed by TAp63 
and ΔNp63 transcriptional activities, we refined TAp63 tumor suppressive and 
ΔNp63 oncogenic signatures (135) based on a survival-predictive model dubbed 
Pan Cancer Survival Signature (PCSSTAp63 and PCSSΔNp63, respectively). PCSSTAp63 
activity significantly decreased across various Stages I to IV cancers, including 
breast (BRCA), kidney clear cell (KIRC), and kidney papillary (KIRP), lung 
adenocarcinoma (LUAD), and lung squamous cell (LUSC) carcinoma  
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Figure 17: Tissue and stage-dependent activities of TAp63 and ∆Np63 in tumor 
development and progression. A, Working model for identification of 
transcriptional networks enriched in TCGA tumors. B, Summary of GSEA 
concordant findings across in cancer development and cancer progression 
signatures. Reproduced with permission from Abbas*, Bui* et al., Cancer Research 
(2018) 78(2), 451–62     
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(ANOVA<0.0001-0.032), exhibiting a consistent tumor suppressor pattern (Figure 
18A). PCSSΔNp63 activity, on the other hand, increased significantly from Stage I to 
IV in BRCA and LUAD (ANOVA<0.0001), patterning an oncogenic role (Figure 18B).  
Strikingly, patients with increased activity of PCSSTAp63 and PCSSΔNp63 had 
significantly better and worse overall survival, respectively, within stages and across 
all patients (p<0.0001-0.038) (Figure 18C-D). Both PCSSTAp63 and PCSSΔNp63 
signatures showed enrichments in pathways involved in metabolism and cell cycle 
(Figure 18E-F). Taken together, these data demonstrated tumor-suppressive roles of 
TAp63 and tumor-promoting roles of ∆Np63 in majority of cancers analyzed in 
TCGA. More interestingly, these signatures can further be utilized to predict patient 
survival.  
 
4.2.3 ΔNp63 plays a pleiotropic role as a tumor suppressor or oncogene 
during tumor development 
Since ∆Np63 exhibits functional pleiotropic roles in tumor development where 
it exerts oncogenic activities in some cancers and tumor suppressive activities in 
others, the basal expression level of ∆Np63 may vary among different cancers. 
Based on the TCGA analysis across multiple cancers (Figure 17B), ∆Np63 was 
shown to function as an oncogene in breast cancer (BRCA) and lung squamous cell 
carcinoma (LUSC) while displaying tumor suppressive functions in kidney clear cell 
(KIRC). The expression of ∆Np63 was examined in cell lines derived from these 
cancers, including MCF10-CA1D (BRCA), HCC95 (LUSC) and Caki-1 (KIRC).   
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Figure 18: TAp63 and ΔNp63 signatures predict patient survival. A-B, Heatmap 
of the activity of PCSSTAp63 (A) and PCSSΔNp63 (B) across different stages of 
tumorigenesis. C-D, Dot plot of the survival analysis of different tumors with respect 
to PCSSTAp63 (C) and PCSSΔNp63 (D). E-F, -Log10(p-value) of pathways enriched in 
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PCSSTAp63 (E) and PCSSΔNp63 signatures (F). Reproduced with permission from 
Abbas*, Bui* et al., Cancer Research (2018) 78(2), 451–62 
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Interestingly, ∆Np63 is highly expressed in MCF10-CA1D and HCC95 while 
remaining undetectable in Caki-1 cells (Figure 19A). This observation is in 
accordance with respective roles of ∆Np63 in those tumor types. Next, I asked if 
manipulation of ∆Np63 level in these cells would result in opposing effects on their 
oncogenic activities. Thus, ∆Np63 was knocked down using specific si∆Np63 in 
MCF10-CA1D and HCC95 and overexpressed in Caki-1 cells (Figure 19B). ∆Np63α 
was used for the overexpression as it is the predominant isoform of ∆Np63 found in 
majority of cancers (18).  
Knockdown of ΔNp63 in MCF10-CA1D breast cancer cells reduced 
proliferation and soft agar colony formation (Figure 20A-D).  In HCC95 LUAD cells, 
knockdown of ∆Np63 decreased soft agar colony formation but not proliferation 
(Figure 20E-H), suggesting oncogenic functions of ∆Np63 in BRCA and LUAD. To 
assess tumor suppressor activities of ΔNp63, ΔNp63α was overexpressed in Caki-1 
cells, and while no significant difference in proliferation was observed (Figure 20J-I), 
the number of colonies on soft agar decreased by 2-fold compared to control (Figure 
20K-L), indicating tumor suppressive activities of  ΔNp63 in KIRC. Taken together, 
these data further support that ∆Np63 plays a pleiotropic role depending on tissues 
of origin. 
4.2.4 ΔNp63 activates an oncogenic program through transcriptional 
regulation of its downstream target, Lef1  
To identify the pleiotropic mechanism exerted by ΔNp63 in tumorigenesis, our 
TCGA derived signatures were overlapped with previously published human ∆Np63 
Chip-Seq data (137), which revealed enrichment for EMT genes. Next,   
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Figure 19: Differential expression of ΔNp63 in MCF10-CA1D, HCC95 and Caki-1 
cells. A, Western blot analysis for ΔNp63 expression in MCF10-CA1D, HCC95 and 
Caki-1 cells. NHEK-WT and NHEK-shΔNp63 were used as positive and negative 
control for ΔNp63 expression. Actin was used as internal loading control. B, Western 
blot analysis for either ΔNp63 knockdown efficiency in MCF10-CA1D and HCC95 
treated with either siC or siΔNp63, or ΔNp63 overexpression in Caki-1 cells treated 
with either empty vector (EV) or ΔNp63α-overexpressing plasmid (ΔNp63α). 
Reproduced with permission from Abbas*, Bui* et al., Cancer Research (2018) 78(2), 
451–62  
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Figure 20: ΔNp63 plays a pleiotropic role as a tumor suppressor or oncogene. 
A-D, E-F,I-J, Quantification and fluorescence representative images of EdU (green) 
incorporation  MCF10-CA1D (A-B), HCC95 (E-F) and Caki-1 (I-J) cell lines. C-D,    
G-H, K-L, Quantification and bright field representative images of anchorage-
independent colony formation of MCF10-CA1D (C-D), HCC95 (G-H) and Caki-1 (K-
L) cell lines in soft agar assay (per 10X field). Data are mean ± SD, n = 3. Asterisks 
indicate statistical significance, p < 0.005 versus siRNA scramble control (siC) or 
empty vector (EV), two-tailed t test. Reproduced with permission from Abbas*, Bui* 
et al., Cancer Research (2018) 78(2), 451–62 
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hypergeometric analysis was conducted to identify transcription factors that regulate 
these EMT genes and overlapped with ΔNp63 keratinocyte signatures. Several Lef1 
targets (INHBA, USP2, COL5A1, BMP1, PMEPA1) were identified to be highly 
significant (p=0.0009). Therefore, to assess whether ∆Np63 exerts its oncogenic 
functions through Lef1, Lef1 expression at mRNA and protein level in MCF10-CA1D 
and HCC95 cell lines was determined upon ∆Np63 knockdown. Indeed, Lef1 
expression decreased (Figure 21A-B), indicating that Lef1 is downstream of ΔNp63. 
More interestingly, depletion of Lef1 using siRNAs in both MCF10-CA1D and HCC95 
cell lines (Figure 21C) reduced colony formation in soft agar similar to what was 
observed when ΔNp63 was knocked down in these cells (Figure 21D-G). In addition, 
overexpressing Lef1 in ΔNp63-depleted cells (Figure 22A) significantly increased 
MCF10-CA1D and HCC95 colony formation (Figure 22B-E), and MCF10-CA1D cell 
proliferation (Figure 22F-G), but not HCC95 proliferation (Figure 22H-I). Together, 
these data demonstrated that ∆Np63 functions as an oncogene via regulating Lef1 in 
MCF10-CA1D BRCA and HCC95 LUSC cells.  
 
4.2.5 Lef1 is a downstream target of ΔNp63, but fails to exert tumor 
suppressive functions of ΔNp63 in Caki-1 cells 
In Caki-1 cells where ΔNp63 functions as a tumor suppressor, the 
overexpression of ∆Np63 upregulated Lef1 mRNA and protein expression (Figure 
23A-B), which further confirmed that ΔNp63 regulates Lef1 expression. Then, to 
assess whether the tumor suppressive role of ∆Np63 functions through Lef1, Lef1   
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Figure 21: Lef1 is a downstream target of ΔNp63 in MCF10-CA1D and HCC95. 
A, qRT-PCR for Lef1 in MCF10-CA1D and HCC95 cells expressing either siC or 
siΔNp63. Asterisks indicate statistical significance, p < 0.005 versus siC, two-tailed t 
test. B-C, Western blot analysis for: Lef1 expression in MCF10-CA1D and HCC95 
cells expressing either siC or siΔNp63 (B) or in MCF10-CA1D and HCC95 cells 
treated with siC, siLef1-1 or siLef1-2 (C). Actin was used as a loading control. D-G, 
Quantification and bright field representative images of anchorage-independent 
colony formation of indicated cell lines in soft agar assay (per 10X field). Data are 
mean ± SD, n = 3. Asterisks indicate statistical significance, p < 0.005 versus siC or 
siΔNp63, two-tailed t test. Reproduced with permission from Abbas*, Bui* et al., 
Cancer Research (2018) 78(2), 451–62 
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Figure 22: ΔNp63 exerts it oncogenic activities via Lef1 in MCF10-CA1D and 
HCC95 cells. A, Western blot analysis for ΔNp63 and Lef1 expression in MCF10-
CA1D and HCC95 cells treated with siΔNp63 and Lef1-overexpressing plasmid 
(Lef1). Actin was used as internal loading control. B-E, Quantification and bright field 
representative images of anchorage-independent colony formation of indicated cell 
lines in soft agar assay (per 10X field). Data are mean ± SD, n = 3. Asterisks 
indicate statistical significance, p < 0.005 versus siC or siΔNp63, two-tailed t test. F-
I, Quantification and fluorescence representative images of EdU (green) 
incorporation of indicated cell lines. Data are mean ± SD, n = 3. Asterisks indicate 
statistical significance, p < 0.05 versus siC or siΔNp63, two-tailed t test. Reproduced 
with permission from Abbas*, Bui* et al., Cancer Research (2018) 78(2), 451–62 
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was overexpressed in Caki-1 cells, resulting in a non-statistically significant 
decrease in soft agar colony formation (Figure 23C-E). However, when Lef1 was 
knocked down in Caki-1 cells overexpressing ΔNp63α (Figure 23F), no significant 
difference was observed in cell proliferation and colony formation (Figure 23G-J), 
suggesting the involvement of other factors than Lef1 in the tumor suppressive roles 
of ΔNp63. Hence, ∆Np63 regulation of Lef1 dictates its oncogenic roles in different 
tissues while the tumor suppressor pathways of ∆Np63 are not yet identified. 
 
4.2.6 ΔNp63-regulated transcriptional activities are lost in higher stages and 
can predict survival of BLCA, KIRC, KIRP and LGG 
GSEA analysis revealed a suppressive role for ΔNp63 in the progression of 4 
tumors: bladder cancer (BLCA), KIRC, KIRP and low grade glioma (LGG). To 
explore the role of ΔNp63 in tumor progression, ΔNp63-regulated genes that were 
enriched in cancer progression signatures and the corresponding isoform signature 
were identified, hereafter dubbed ΔNp63BLCA, ΔNp63KIRC, ΔNp63KIRP and ΔNp63LGG  
(Figure 24A-B). Interestingly, high grade/stage BLCA, KIRC, KIRP and LGG had 
significantly lower activities of their corresponding ΔNp63-driven signature compared 
to low grade/stage tumors (p<0.0001), suggesting that higher grade/stage tumors 
lose ΔNp63 activities upon progression (Figure 24C). Further, KIRC (p<0.0001) and 
LGG (p<0.0001) patients with higher corresponding ΔNp63 activity had significantly 
better survival than patients with lower activity (Figure 24D). Association between 
activity and survival was also evident within the same grade/stage of tumors (Figure 
24E). This is of particular importance as it suggests that there is significant 
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Figure 23: Lef1 is a downstream target of ΔNp63 in Caki-1. A, qRT-PCR for Lef1 
in Caki-1 cells expressing either empty vector (EV) or ΔNp63α-overexpressing 
plasmid (ΔNp63α). Asterisks indicate statistical significance, p < 0.005 two-tailed t 
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test. B, Western blot analysis for Lef1 in Caki-1 cells expressing either empty vector 
(EV) or ΔNp63α-overexpressing plasmid (ΔNp63α). Actin was used as internal 
loading control. C, Western blot analysis for Lef1 overexpression efficiency in Caki-1 
cells expressing either with empty vector (EV) or ΔNp63α-overexpressing plasmid 
(ΔNp63α). Actin was used as internal loading control. D-E, Quantification and bright 
field representative images of anchorage-independent colony formation of indicated 
cell lines in soft agar assay (per 10X field). Data are mean ± SD, n = 3. F, Western 
blot analysis for ΔNp63 and Lef1 expression in Caki-1 cells treated with ΔNp63α-
overexpressing plasmid (ΔNp63α) and siLef1. Actin was used as internal loading 
control. G-H, Quantification and fluorescence representative images of EdU (green) 
incorporation of indicated cell lines. Data are mean ± SD, n = 3. I-J, Quantification 
and bright field representative images of anchorage-independent colony formation of 
indicated cell lines in soft agar assay (per 10X field). Data are mean ± SD, n = 3. 
Asterisks indicate statistical significance, p < 0.0005 versus EV, two-tailed t test. 
Reproduced with permission from Abbas*, Bui* et al., Cancer Research (2018) 78(2), 
451–62 
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heterogeneity in the activity of ΔNp63 within high stages of KIRC, KIRP and LGG 
that may warrant different therapy.  
 
4.2.7 Pluripotency potential, EMT and ECM remodeling in high stage tumors 
are modulated by ΔNp63 signatures 
In the ΔNp63-derived signatures, there were 2 genes (CTHRC1 and COL5A1 
both are major ECM constituents) and 14 pathways that were common among 
ΔNp63BLCA, ΔNp63KIRC, ΔNp63KIRP and ΔNp63LGG (135). The highest enrichments in 
ΔNp63 signatures were developmental and extra cellular matrix (ECM) remodeling 
pathways (Figure 25A) which are indicative of stem cell pluripotency, EMT, and 
metastatic mechanisms. Therefore, we investigated whether previously published 
stem cell, ECM and EMT signatures were enriched in high grade/stage tumors and 
ΔNp63-/- keratinocytes. Interestingly, GSEA analyses identified a significant 
enrichment of cancer invasive and primary stem cells (138, 139), mouse and human 
embryonic stem cell signatures (140, 141), Nanog, Oct4 and Sox2 (NOS) targets 
(140) and primary tumor and metastatic ECM signatures (142)  in high grade/stage 
tumors and ΔNp63-/- epidermal cells signatures (Figure 25B-C). In addition, a 
significant enrichment of EMT in ΔNp63-/- keratinocytes and progression signatures 
of BLCA, KIRC and KIRP was also observed (Figure 25D), which is consistent with 
our observations on the induction of EMT upon depletion of ΔNp63.  
In summary, the suppressive activity of ΔNp63 in tumor progression is 
consistent with previous reports indicating that ΔNp63 promotes differentiation of 
epithelial tissues and that loss of ΔNp63 leads to EMT and pluripotency (7, 143). 
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Figure 24: Tumor suppressor activity of ΔNp63 in cancer progression. A, 
Circos plots of the overlap and expression of ΔNp63 signatures with progression 
signatures of BLCA, KIRC, KIRP and LGG. B, Normalized enrichment score (NES) 
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of upregulated and downregulated cancer progression signatures in TAp63-/- and 
ΔNp63-/- signatures. C, Activity score of ΔNp63BLCA, ΔNp63KIRC, ΔNp63KIRP and 
ΔNp63LGG in corresponding cancer patients at high and low grade/stages. D, Kaplan-
Meier survival of BLCA, KIRC, KIRP and LGG patients with respect to the 
corresponding ΔNp63 signature activity. E, Kaplan-Meier survival within Stage IV 
KIRC, and G2 and G3 LGG patients with respect to ΔNp63KIRC and ΔNp63LGG 
activities, respectively. Number of cases in each survival group is listed between 
parenthesis where indicated. Reproduced with permission from Abbas*, Bui* et al., 
Cancer Research (2018) 78(2), 451–62 
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The progression of these tumors entails loss of ΔNp63 transcriptional activities, 
which leads to increased stem cell pluripotency, ECM remodeling, and EMT, leading 
to tumor progression and metastasis (Figure 25E). These findings identify patients 
within different stages that could benefit from treatments that specifically target these 
pathways.  
  
96  
 
Figure 25: Enrichment of pluripotency, ECM and EMT in ΔNp63 driven 
progression signatures. A, Log10(p-value) of pathways enriched in ΔNp63BLCA, 
ΔNp63KIRC, ΔNp63KIRP and ΔNp63LGG. B-D, Normalized enrichment scores (NES) of 
bladder cancer (BLCA), kidney clear cell (KIRC), kidney papillary (KIRP) and low 
grade glioma (LGG) progression and ΔNp63-/- signatures in (B) known stem cells 
and pluripotency, (C) ECM and (D) EMT signatures. E, Suggested model for ΔNp63 
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to suppress tumor progression via modulation of EMT, ECM, pluripotency and cell 
cycle activity. Reproduced with permission from Abbas*, Bui* et al., Cancer 
Research (2018) 78(2), 451–62 
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Chapter 5: Dynamic regulation of ∆Np63 during breast cancer progression and 
metastasis 
 
5.1 Introduction and Rationale 
Since the discovery of different p63 isoforms with distinct physiological and 
pathological functions, ∆Np63 has been shown by numerous studies to exert 
oncogenic activities in cancers (25-27). This notion mostly arose from the fact that 
∆Np63 is found to be highly expressed in primary tumors and metastases of multiple 
cancers (144-146). In addition, several studies have reported anti-tumor effects 
when ∆Np63 was depleted in the primary tumors (25, 27). Inhibitory effects of ∆Np63 
on EMT and potentially metastasis have also been documented, which is in contrast 
to its oncogenic roles observed in primary tumors, as discussed in details in section 
1.3.4 and 1.4.2. However, these studies mainly focused on either in vitro 
characterization or snapshot events of the multistep process of metastatic cascade, 
yet failed to investigate contributions of ∆Np63 from the establishment of primary 
tumors to the formation of distant metastases in vivo. Of note, the loss of ΔNp63 in 
epithelial-like bladder cancer cells promotes EMT and enhance invasion, while the 
induction of ΔNp63 in mesenchymal-like bladder cancer cells triggers MET and 
suppresses cancer cell invasion (31), suggesting a dynamic regulation of ∆Np63 
during EMT and metastasis. Moreover, we have recently demonstrated pleiotropic 
functions of ∆Np63 during tumor development and progression using a global 
approach on various types and stages of cancers (135). Together, these opposing 
findings suggest a more intricate involvement of ∆Np63 during cancer progression 
  
100  
and metastasis. Perhaps, ∆Np63 has a two-faceted role in cancer progression and 
metastasis, which is similar to many important pathways in cancers such as TGFβ 
signaling. Thus, I hypothesize that while ∆Np63 is required for primary tumor growth, 
the loss of ΔNp63 in tumor cells at primary sites promote the dissemination of tumor 
cells into circulation, whereas ΔNp63 expression is essential for circulating tumor 
cells (CTCs) to colonize and form macro-metastases at distant organs (Figure 26). 
More importantly, the identification of upstream regulators of ΔNp63 during this 
process will propose potential biomarkers and treatments for metastatic cancers. 
From our pan-cancer analyses using TCGA, ΔNp63 showed oncogenic 
activities in the development of breast cancer, whereas we did not obtain significant 
data for the progression of this cancer. Given that the roles of ΔNp63 in breast 
cancer remain very controversial due to conflicting observations from different 
studies, I aimed to decipher the dynamic regulation of ΔNp63 in an in vivo breast 
cancer model in order to ultimately provide a comprehensive insight into the 
contribution of this isoform from the establishment of primary breast tumors to 
metastatic dissemination to distant lungs. 
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Figure 26: Proposed working model for the dynamic regulation of ΔNp63 in 
cancer progression and metastasis. At primary tumors, ΔNp63 is highly 
expressed and required for tumor growth. In invading tumor cells, the loss of ΔNp63 
promotes the dissemination of tumor cells into circulation. At distant sites, arrested 
circulating tumor cells (CTCs) re-express ΔNp63 to colonize and form macro-
metastases at distant organs 
 
5.2 Results 
5.2.1 Clinical correlation between ΔNp63 expression and breast cancer 
progression 
First, we asked if there is any correlation between ΔNp63 and breast cancer 
patient survival reported in TCGA database. Interestingly, low expression of ΔNp63 
correlates with worse survival in patients with Stage III breast cancer (Figure 27A-C), 
connecting the loss of ΔNp63 in advanced stage-primary tumors with poor 
prognosis. In accordance with this result, immunostaining for ΔNp63 expression in 
breast cancer tissue microarrays (TMA) with a spectrum of different stages of breast 
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cancer revealed a significantly decreased expression of ΔNp63 in invasive breast 
cancer samples (Figure 27D-E). In another breast cancer TMA with primary tumors 
and corresponding lymph node metastases, there is a positive correlation for 
expression level of ΔNp63 in primary tumors and their matched metastases (referred 
as a “pair of sample”) (Figure 28A). Next, in order to analyze more details into the 
expression pattern of ΔNp63 in primary tumors and corresponding metastases, pairs 
of samples were classified into four groups based on the intensity of ΔNp63 staining: 
high ΔNp63 in both primary and metastases, low ΔNp63 in both primary and 
metastases, high ΔNp63 in primary and low ΔNp63 in metastases, low ΔNp63 in 
primary and high ΔNp63 in metastases. Interestingly, the pattern of high ΔNp63 in 
both primary and metastases has the highest percentage of samples in all 3 stages 
of breast cancer (Figure 28B). This observation is in accordance with the previous 
reports on high expression of ΔNp63 in both primary tumors and metastases. 
Strkingly, there is an increase in samples with pattern of low ΔNp63 in primary and 
high ΔNp63 in metastases from stage IIA to IIIA, indicating an increasing loss of 
ΔNp63 in primary tumors while the matched metastases still retained expression of 
ΔNp63 when tumors progressed (Figure 28B). Together, these data point out the 
clinical connection between decreased expression of ΔNp63 and tumor progression 
in breast cancer.  
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Figure 27: Low ΔNp63 expression in advanced breast cancer correlates with 
worse patient survival. A-B, Kaplan-Meier survival within Stage III breast cancer 
patients with respect to low and high expression of ΔNp63α (A), ΔNp63β (B) and 
ΔNp63γ (C). D, Immunohistochemistry staining for ΔNp63 in breast cancer tissue 
microarray. E, Quantification of ΔNp63 expression (score) in breast cancer tissue 
microarray. Score of each sample was determined by number of positive nuclei and 
average staining intensity. Asterisks indicate statistical significance, p < 0.005.  
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Figure 28: Expression level of ΔNp63 in human breast primary tumors and 
corresponding lymph node metastases assessed by immunostaining for 
ΔNp63 in human tissue microarray. A, Correlation plot for ΔNp63 expression 
(score) in primary tumors and corresponding metastases. B, Distribution plot for ratio 
of different ΔNp63 expression pattern between primary tumors and metastases at 
different stages of breast cancer.             
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5.2.2 Generating an inducible shRNA against ΔNp63 to conditionally knock 
down ΔNp63 in vivo 
A limitation of majority of the studies on ΔNp63 is the lack of shRNAs 
specifically targeting ΔNp63 (shΔNp63). Due to the complexity at the TP63 locus, 
most commercially available shRNAs target the DNA-binding domain (DBD) which is 
common for both TAp63 and ΔNp63. Hence, specific shRNA for ΔNp63 targeting the 
3’exon unique for the isoform only was designed. This shRNA was then cloned into 
a doxycycline-inducible vector to express shRNA (Clontech). Next is the request for 
a breast cancer cell line in which ΔNp63 could be manipulated in vivo to assess for 
tumor establishment and metastatic formation. MCF10 progression model includes a 
series of human mammary epithelial cell lines, malignant and non-malignant, which 
were derived from the normal mammary epithelial cells MCF10A (10A) (147-149). 
Among those cell lines, MCF10-DCIS (DCIS) cells formed comedo-like DCIS 
structures, but exhibited very low spontaneous metastatic frequency to lungs and 
livers when injected into mammary fat pads of nude mice. MCF10-CA1D (CA1D) 
cells formed poorly differentiated tumors and have spontaneous metastases to lungs 
and livers (Figure 29A). Therefore, DCIS cell were infected with inducible-shΔNp63 
lentivirus to generate a stable cell line expressing the inducible-shΔNp63 (DCIS-i-
shΔNp63). In the presence of doxycycline (dox), ΔNp63 level was decreased after 3 
days and started to come back two days after withdrawing dox from the media 
(Figure 29B), indicating a successful manipulation of ΔNp63 using doxycycline in 
vitro. These cells were next injected into nude mice to assess tumor and metastatic 
formation. 
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Figure 29: Generating MCF10-DCIS cell line expressing doxycycline-inducible 
sh∆Np63. A, H&E sections of primary tumors, lung and liver metastases of 
MCF10A, MCF10-DCIS and MCF10-CA1D cells injected into mammary fat pads of 
nude mice. B, Western blot for ∆Np63 in MCF10DCIS-i-sh∆Np63 in the presence of 
doxycycline. Actin was used as loading control.   
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5.2.3 ΔNp63 promotes the establishment of primary tumors 
The depletion of ΔNp63 by shΔNp63 upon doxycycline induction reduced cell 
proliferation in vitro (Figure 30A-B), confirming tumor-promoting activities of ΔNp63 
in primary tumors. In order to determine if ΔNp63 is essential for the establishment 
of primary tumors of breast cancer cells in vivo, DCIS-i-shΔNp63 cells were cultured 
in dox for 3 days prior to injection to mammary fat pads of nude mice. The mice were 
then fed with either control or dox diet to induce expression of shΔNp63 in vivo. After 
4 weeks, primary tumors were dissected out and measured for tumor volume (Figure 
30C). The results demonstrated that cohort of mice on dox diet had significantly 
smaller tumors compared to control diet mice (Figure 29D), suggesting that ΔNp63 
is essential for the establishment of primary breast cancer in vivo.  
 
5.2.4 ΔNp63 is required for lung extravasation and colonization of circulating 
tumor cells 
Since ΔNp63 promotes the formation of primary tumors, the next question is 
whether ΔNp63 is also required for the establishment of distant metastases to the 
lungs. There are two critical steps involved in the formation of overt metastatic 
colonies at distant organs: extravasation and colonization. In order to determine 
roles of ΔNp63 in extravasation of circulating tumor cells into the lungs,             
DCIS-i-shΔNp63 cells were labeled with RFP using lentivirus expressing RFP. Next, 
these cells were cultured in dox for 3 days. Control cells were cultured in media 
without dox. The cells were then injected intravenously into nude mice via tail vein. 
Mice injected with control cells were fed with control diet (group 1). Mice injected  
  
108  
 
Figure 30: ∆Np63 promotes the establishment of primary tumors. A, Western 
blot for ∆Np63 in DCIS-i-sh∆Np63 cells upon dox treatment. B, Growth curves for 
DCIS-i-sh∆Np63 cells with or with dox treatment. C, Experimental design to 
determine roles of ∆Np63 in primary tumors. D, Tumor volume (mm3) from nude 
mice injected with DCIS-i-sh∆Np63 and fed with either control diet or dox diet. 
Asterisk indicate statistical significance, p < 0.05 versus No dox diet . two-tailed t 
test. 
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with dox-treated cells were fed with either control diet (group 2) or dox diet (group 3). 
After 48 hours, the lungs were collected and dissociated to get single cells for flow 
cytometry assay to detect RFP-positive cells successfully extravasating into the 
lungs (Figure 31A). The results showed that mice fed with dox diet (group 3) had a 
decrease in number of RFP-positive cells in the lungs compared to mice fed with 
control diet (group 1). Interestingly, mice injected with dox-treated cells but fed with 
control diet (group 2) had similar percentage of RFP-positive cells to control group 1 
(Figure 31B-C), indicating that ΔNp63 was essential for circulating cells to 
extravasate into the lungs at early stage of lung colonization. A similar approach was 
used to determine if ΔNp63 is also necessary for the formation of macro-metastases 
in the lungs. In this experiment, the mice were aged till 8 weeks post-injection, then 
the lungs were collected and quantified for number of metastatic nodules and micro-
metastases (Figure 32A). Similar to previous observation, group 1 and group 2 had 
non-statistical significance in the number of both visible nodules and metastatic 
colonies in the lungs, while group 3 exhibited a dramatic reduction in metastasis 
formation (Figure 32B-E). Surprisingly, metastases in all three experimental groups 
showed high expression of ΔNp63 (Figure 32F), suggesting that cells expressing 
ΔNp63 might have greater advantage to colonize distant lungs. Taken together, 
these in vivo data demonstrated that ΔNp63 is required for both extravasation and 
colonization of tumor cells at distant lungs.   
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Figure 31: ∆Np63 is required for lung extravasation of circulating tumor cells. 
A, Experimental design to investigate roles of ∆Np63 in extravasation to the lungs of 
tumor cells. B-C, Flow cytometry assay (B) and quantification (C) of the percentage 
of RFP-positive cells extravasating to the lungs. Asterisk indicate statistical 
significance, p < 0.05 versus group 2. ns, non-statistical significance. two-tailed t 
test.  
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Figure 32: ∆Np63 enhances lung colonization and formation of metastatic 
colonies. A, Experimental design to investigate roles of ∆Np63 in lung colonization. 
B-C, Bright field images of lung tissues (B) and quantification of visible lung nodules 
per mouse (C). Asterisk indicate statistical significance, p < 0.0005 versus group 2. 
ns, non-statistical significance. two-tailed t test. D-E, H&E sections of lung tissues 
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(D) and quantification of micro- and macro-metastatic colonies per lung section per 
mouse (E). Asterisk indicate statistical significance, p <0.0005 versus group 2 . ns, 
non-statistical significance. two-tailed t test. F, Immunohistochemistry staining for 
∆Np63 in metastatic colonies in the lungs.  
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5.2.5 Dynamic regulation of ∆Np63 enhances metastatic colonization to the 
lungs 
My in vivo data have shown that ∆Np63 is necessary for the formation of both 
primary tumors and metastases when we investigated each step of metastatic 
cascade separately. The remaining important question is how ∆Np63 expression 
affects the process of metastatic dissemination as a whole, from primary tumor 
formation to lung colonization. In order to address this question, DCIS-i-sh∆Np63 
cells were injected into mammary fat pads of nude mice, then waited for 2 weeks for 
tumors become palpable. After that, the mice were fed either with control diet (group 
1) or dox diet for 3 weeks. Then, one group of mice on dox diet was switched back 
to control diet (group 2), while the other group was on dox diet (group 3) for another 
3 weeks. After 3 more weeks, the mice were sacrificed for primary tumors and lungs 
to assess metastatic frequency (Figure 33A). Consistent with our previous findings, 
the depletion of ∆Np63 in established tumors also reduced tumor growth (Figure 
33B). Primary tumors from group 3 showed lower expression of ∆Np63 and Ki67 
compared to group 1 and 2, indicating that the loss of ∆Np63 decreased tumor cell 
proliferation which led to reduced tumor growth (Figure 33C-D). Strikingly, mice on 
dox diet for 3 weeks then control diet for 3 weeks (group 3) showed the highest 
metastatic frequency among three groups. Interestingly, mice continuously fed with 
dox diet for 6 weeks (group 3) had higher metastatic frequency than the control diet 
group (group 1) (Figure 33E). In addition, metastases in the lungs from all three 
groups were positive for ΔNp63 staining (Figure 33F), suggesting that a subset of 
cells that managed to escape the knockdown effect of the shRNA or regain  
  
114  
 
Figure 33: Dynamic regulation of ∆Np63 enhances metastatic colonization to 
the lungs. A, Experimental design to investigate the dynamic regulation of ∆Np63 in 
cancer metastasis. B, Tumor volume (mm3) of mice injected with DCIS-i-sh∆Np63 
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cells and fed with different diet schedules. Asterisk indicate statistical significance, p 
<0.05 versus group 1 or group 2. ns, non-statistical significance. two-tailed t test. C, 
Immunohistochemistry for ∆Np63 and Ki67 in primary tumors. D, Western blot for 
∆Np63 in lysates from primary tumors. Actin was used as loading control. E, 
Metastatic frequency to the lungs. F, Immunohistochemistry for ∆Np63 in primary 
tumors and lung metastases.  
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expression of ∆Np63 were able to colonize the lungs. These data further revealed 
that the loss of ΔNp63 in the primary tumors facilitates metastasis, whereas the re-
expression of ΔNp63 in circulating cells is essential for the establishment of distant 
metastases.  
 
5.2.6 TGFβ signaling inhibits expression of ΔNp63 in breast cancer 
Given that the dynamic regulation of ΔNp63 plays important roles in 
metastatic dissemination, it is necessary to identify upstream regulators of ΔNp63 in 
the process in order to propose potential targeted therapy and biomarkers that 
connect ΔNp63 with breast cancer progression. TGFβ signaling has been shown to 
have dual roles in breast cancer development and metastasis. In normal cells and 
early stage tumors, TGFβ exerts its tumor suppressive functions to inhibit 
tumorigenesis via inducing apoptosis and cell growth arrest. In contrast, in advanced 
cancer, TGFβ functions as a pro-metastatic factor by inducing EMT and promoting 
breast cancer cell migration and invasion, which ultimately favors metastatic 
dissemination (150, 151). Interestingly, a recent study revealed that a constitutive 
activation of TGFβ signaling promotes single cell invasion and intravasation in 
primary tumors, but fails to facilitate tumor growth of distant metastases, whereas a 
localize and reversible TGFβ signaling is required for bone metastatic dissemination 
of breast cancer (107). This mechanism of action resembles our observations on 
functions of ΔNp63 in multistep process of metastatic cascade, suggesting a 
possible regulatory network connecting TGFβ signaling and ΔNp63.    
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Figure 34: TGFβ signaling inhibits expression of ΔNp63 in breast cancer. A, 
Bright field images of DCIS cells expressing shΔNp63 or treated with TGFβ. B-D, 
Western blot for indicated antibodies in 10A, DCIS and CA1D cells treated with 
TGFβ (B) or with TGFβ and LY2157299 (C) or with TGFβ and siSmad3 (D). Actin 
was used as loading control.  
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Indeed, in the presence of TGFβ, DCIS cells shared similar morphology to 
ΔNp63-depleted cells (Figure 34A). Strikingly, ΔNp63 expression was dramatically 
reduced in the presence of TGFβ in 10A, DCIS and CA1D cells. Increased 
phosphorylation of Smad2/3 was also observed in all three cell lines (Figure 34B), 
indicating that TGFβ may potentially inhibit ΔNp63 expression via Smad2/3 
transcriptional activities. To further confirm the regulation of ΔNp63 by TGFβ 
signaling, the cells were treated with LY2157299, an inhibitor of TGFβ-receptor I 
(TGFβRI), to inactivate TGFβ signaling cascade. The results showed that the 
inhibition of ΔNp63 expression by TGFβ was rescued in the presence of LY2157299 
(Figure 34C). TGFβ signaling is transduced through either canonical Smad-
dependent pathways or non-canonical Smad-independent pathways (152). 
Knockdown of Smad3 in 10A and DCIS cells prevented TGFβ-induced reduction of 
ΔNp63 (Figure 34D), suggesting the connection between TGFβ and ΔNp63 through 
Smad2/3 complex.  
 
5.2.7 TGFβ-induced microRNAs regulate expression of ΔNp63 
In order to determine whether there is a direct transcriptional repression of 
Smad2/3 complex on the expression of ΔNp63, mRNA level of ΔNp63 upon TGFβ 
induction was examined. Nevertheless, no significant reduction of ΔNp63 mRNA 
was observed in the presence of TGFβ (Figure 35A), whereas its protein level was 
dramatically decreased (Figure 35B). This suggests there may not be a direct 
transcriptional regulation of Smad2/3 at the promoter of ΔNp63. Thus, the 
involvement of other regulatory mechanisms may account for the regulation of 
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ΔNp63 by TGFβ signaling. microRNAs have been intensively studied for their roles 
in post-transcriptional regulation of gene expression. Crosstalk between TGFβ and 
microRNA machinery have been reported in multiple cancers (153). Hence, 
differential expressed microRNAs in DCIS cells upon TGFβ induction was profiled 
using NanoString nCounter human microRNA platform. The results identified 74 up-
regulated microRNAs upon TGFβ treatment (Figure 35C). Then, these microRNAs 
were merged with a list of microRNAs predicted to have binding sites to the 3’UTR of 
TP63 gene by miRWalk. This approach resulted in 64 microRNAs that may 
potentially bind to 3’UTR of TP63 and regulate ΔNp63 expression upon activation of 
TGFβ signaling (Figure 35D). Among the 64 microRNAs, 9 microRNAs, including 
miR-10b, miR-21, miR-22, miR-30a, miR-141, miR-181a, miR-200a, miR-203a and 
miR-222, were selected for further validation based on predicted binding affinity to 
3’UTR of TP63 and previously reported connection with breast cancer or ΔNp63. 
Overexpressing mimics of these 9 microRNAs demonstrated that miR-22, miR-30a, 
miR-203a and miR-222 were able to down-regulate ΔNp63 protein level in DCIS 
cells (Figure 36A). Similar results were obtained in 10A and CA1D cells (Figure 
36B). Moreover, these 4 microRNAs showed direct interaction with the 3’UTR of 
TP63 gene in luciferase assay (Figure 36C-J), confirming regulatory effects of these 
4 microRNAs on ΔNp63 expression in breast cancer cells.  
Notably, TGFβ signaling was confirmed to up-regulate expression of these 4 
microRNAs (Figure 37A-D). Chromatin immunoprecipitation data revealed direct 
binding of Smad2/3 to the promoter regions of these 4 microRNAs, proposing the 
regulation of ΔNp63 via TGFβ/microRNAs axis (Figure 37E-H). Interestingly, 
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inhibition of both miR-30a and miR-203a or all 4 microRNAs, but not single 
microRNA, rescued the expression of ΔNp63 in the presence of TGFβ (Figure 37I-
K). This suggests synergistic effects of the microRNAs in regulating ΔNp63 
downstream of TGFβ signaling in breast cancer.  
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Figure 35:  Identification of TGFβ-induced microRNAs that potentially 
regulate ΔNp63 expression. A-B, qRT-PCR (A) and western blot (B) to detect 
ΔNp63 mRNA level upon TGFβ and LY2157299 treatment. Actin was used as 
loading control. C, Heatmap of differential expressed microRNAs between TGFβ-
treated and –non-treated DCIS cells. D, Venn diagram showing 64 TGFβ-
induced microRNAs that are predicted to bind to 3’UTR of p63. 
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Figure 36: miR-22-3p, miR-30a-5p, miR-203a-3p and miR-222-3p regulate 
ΔNp63 expression in breast cancer cells. A, Western blot for ΔNp63 expression 
in DCIS cells transfected with indicated microRNA mimics. B, Western blot for 
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ΔNp63 expression in 10A, DCIS and CA1D cells transfected with miR-22-3p, miR-
30a-5p, miR-203a-3p or miR-222-3p mimics. Actin was used as loading control. C-J, 
Luciferase signal of DCIS cells transfected with 3’UTR of TP63 wild type or mutated 
at binding sites to miR-22-3p (C-D), miR-30a-5p (E-F), miR-203a-3 (G-H), miR-222-
3p (I-J) and indicated microRNA mimics. Asterisk indicate statistical significance,     
p <0.05 versus p63-WT + control mimics. two-tailed t test.                    
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Figure 37: TGFβ represses ΔNp63 expression via miR-22-3p, miR-30a-5p, miR-
203a-3p and miR-222-3p. A-D, Taqman qRT-PCR for expression of miR-22-3p (A), 
miR-30a-5p (B), miR-203a-3p (C) and miR-222-3p (D) upon TGFβ or 
TGFβ+LY2157299 treatment. Asterisk indicate statistical significance, p <0.05 
versus DMSO. two-tailed t test. E-F, Chromatin immunoprecipitation to detect 
binding of Smad2/3 to the promoter of miR-22-3p (E), miR-30a-5p (F), miR-203a-3p 
(G) and miR-222-3p (H) upon TGFβ treatment. Asterisk indicate statistical 
significance, p <0.05 versus control without TGFβ. two-tailed t test. I-J, Western blot 
for ΔNp63 expression in DCIS cells treated with indicated microRNA inhibitors.  
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Chapter 6: Conclusions, Discussion and Future directions 
 
6.1 Conclusions and Discussion 
Adding to current knowledge of the p53/p63/p73 field, my thesis work further 
explored an intricate network of functions of ∆Np63 isoform in physiological and 
pathological processes, especially in cancer progression and metastasis. Firstly, I 
demonstrated that the loss of ∆Np63 in basal epidermal cells triggers an EMT 
program with decreased expression of E-cadherin and increased expression of 
Vimentin, Twist1, Lef1, Snail1 and Zeb1. ∆Np63-deficient keratinocytes exhibit 
increased migration and invasion capacity in vitro. In addition, ∆Np63 depletion in 
basal keratinocytes during wound healing induces an “irreversible” EMT via 
activation of transcription factors Twist1 and Lef1, delaying the wound healing 
process in vivo. I further showed that Twist1 and Lef1 are modulated during the 
induction of EMT upon ∆Np63 depletion via miR-98-3p and miR-34a-5p, 
respectively. These microRNAs are positively regulated by ∆Np63, possibly through 
DGCR8. Together, my findings identify the involvement of a 
∆Np63/microRNAs/Twist1, Lef1 axis in the regulation of EMT in basal epidermal 
cells and wound healing (Manuscript in preparation).  
Secondly, my work revealed pleiotropic roles of ΔNp63 in tumor development 
and progression (135). Specifically, while TAp63 exhibits a consistent tumor 
suppressive role during tumor development and progression among various 
cancers, ΔNp63 plays a pleiotropic role as either a tumor suppressor or an 
oncogene during tumor development in different cancers. In breast cancer (BRCA) 
  
127  
and lung squamous cell carcinoma (LUSC), ΔNp63 activates an oncogenic program 
through transcriptional regulation of its downstream target, Lef1. ΔNp63, on the 
other hand, functions as a tumor suppressor in kidney clear cell carcinoma (KIRC) 
during tumor development. Although Lef1 is also regulated by ΔNp63 in KIRC 
cancer, it fails to exert ΔNp63 tumor suppressive functions in this type of cancer. 
Other factors rather than Lef1 may be responsible for ΔNp63 tumor suppressor roles 
in KIRC cancer. Interestingly, the loss of ΔNp63-regulated transcriptional activities, 
together with enrichment of stem cell, ECM remodeling and EMT signatures are 
observed in higher stages of BLCA, KIRC, KIRP and LGG, suggesting a tumor 
suppressive role of ΔNp63 during cancer progression.  
Thirdly, I further demonstrated that a dynamic regulation of ΔNp63 enhances 
metastatic dissemination in breast cancer. ΔNp63 is essential for primary tumor 
growth, confirming oncogenic roles of ΔNp63 during breast cancer development. 
This observation is in line with previously published studies in other types of cancer 
in our lab (25, 27). ΔNp63 is also required for lung extravasation and subsequent 
colonization to form overt metastatic colonies. Strikingly, continuous depletion of 
ΔNp63 in tumor cells increases metastatic frequency to the lungs compared to 
control mice. More importantly, a modulation of ΔNp63 level during metastatic 
cascade results in highest frequency of metastatic colonization to the lungs, 
indicating that a dynamic regulation of ΔNp63 during breast cancer metastasis 
enhances metastatic dissemination. Additional work revealed a TGFβ/microRNAs 
axis in modulating ΔNp63 expression in breast cancer. The activation of canonical 
Smad-dependent TGFβ signaling down-regulates expression of ΔNp63 via a 
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network of TGFβ-induced microRNAs, including miR-22-3p, miR-30a-5p, miR-203a-
3p and miR-222-3p. These microRNAs cooperatively function to regulate expression 
of ΔNp63 in breast cancer (Manuscript in preparation).  
 
6.1.1 Depletion of ΔNp63 elicits an EMT program in epidermal cells 
∆Np63 is the predominant isoform expressed in the epidermal basal 
keratinocytes and pivotal for the maintenance of stem-like characteristics and the 
terminal differentiation of these cells (16, 33-35). Two studies generated isoform 
specific- knockout mouse models for ∆Np63 and emphasized its role as a master 
regulator of epidermal development. Here, I showed that keratinocytes isolated from 
∆Np63-/- mice undergo dramatic change in morphology from epithelial-like to 
mesenchymal-like with the acquisition of mesenchymal characteristics, revealing 
activation of an EMT program in these cells. Moreover, increased invasiveness was 
also noted in these ∆Np63-deficient keratinocytes. These findings are in line with 
several reports on the induction of EMT upon the depletion of p63 in several cell 
types, including squamous cells, mammary epithelial cells, metastatic prostate 
cancer, cervical cancer and bladder cancer cells (30, 95-97, 154). However, majority 
of these studies used a total p63 knockdown or ∆Np63α/β/γ isoforms overexpression 
approach, which did not take into account the existence of the TAp63 isoforms and 
the complex regulatory network among p63 members.  
By utilizing a ∆Np63-specific knockout mouse model, our data demonstrate 
isoform-specific function of ∆Np63 in modulating EMT in epidermal cells. Especially, 
the depletion of ∆Np63 in keratinocytes results in a complete activation of EMT 
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program with the upregulation of multiple EMT-drivers, including Twist1, Snail1, 
Zeb1 and Lef1 (Figure 8). Zeb1 has been shown to be upregulated upon the 
knockdown of ∆Np63 via direct transcriptional activation of miR-205 in several 
cancer cells (30, 31, 96). Another study also reported decreased expression of 
Twist1, Snail1 and Zeb1 when ∆Np63α was overexpressed in spindle cell 
carcinomas cell lines derived from Trp53ΔEpi;Rb1ΔEp spontaneous skin tumors (155). 
My findings, together with previously published data, consolidate the inhibitory 
effects of ∆Np63 on EMT in various transformed and non-transformed cell lines.  
Given the high expression of ∆Np63 found in majority of epithelial tissues and 
its loss of expression in mesenchymal cells, the regulatory functions of ∆Np63 in 
EMT may serve as a molecular switch between epithelial and mesenchymal state. 
Therefore, down-regulation of ∆Np63 in epithelial cells leads to activation of an EMT 
program, favoring mesenchymal characteristics. Conversely, up-regulation of ∆Np63 
in mesenchymal cells induces an MET program and reverses the cells into epithelial 
state. The fact that keratinocytes in the proliferative basal layer lose expression of 
∆Np63 during terminal differentiation into suprabasal cells further establishes ∆Np63 
as a crucial modulator of cell fate (16, 34, 156). This molecular switch function is 
particularly important during cancer metastasis where tumor cells have to transition 
through a broad spectrum of EMT to shuttle between epithelial and mesenchymal 
state (47). Recently, with more insights into characteristics of metastasizing tumor 
cells, the concept of a reversible “partial” EMT has been increasingly favored in 
explaining the highly plastic nature of tumor cells in order to colonize and spread 
new tumors to distant organs (47, 79, 99). As the center of this EMT regulatory 
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network with the ability to orchestrate multiple EMT-drivers and control cell fate, 
∆Np63 upholds its pivotal roles in many physiological and pathological processes.  
 
6.1.2 Loss of ∆Np63 in epidermal cells delays wound healing process in vivo  
During wound repair process, keratinocytes at the migratory edges of the 
wound undergo a “partial” EMT in order to increase motility and move toward 
wounded sites. Thanks to the plastic nature of this “partial” EMT, the migrating 
keratinocytes can reverse to epithelial state to cover the wound with new layers of 
epithelial cells (43, 47, 74). Since the depletion of ∆Np63 induces a complete EMT in 
which keratinocytes acquire various properties of mesenchymal cells, I hypothesized 
that the complete EMT would prevent or delay wound healing process due to the 
incapability to reverse to epithelial state of ∆Np63-depleted keratinocytes. There are 
studies aiming to develop in vivo models to fully understand mechanisms of action of 
∆Np63 in skin development and homeostasis (157, 158). However, the fact that 
∆Np63-/- mice die shortly after birth with severe defects in skin structure has posed 
great challenges for these studies (5, 7). Koster et al. developed an inducible 
∆Np63-knockdown mouse model to specifically knock down ∆Np63 in epidermal 
cells using si∆Np63 induced upon topical treatment with RU468 (158). With an 
opposite approach, Romano et al. generated a tetracycline-inducible ∆Np63α-
overexpressing mouse model to investigate contribution of ∆Np63 in hair follicle 
development (157). Nevertheless, these models still exhibited certain limitations. 
With Koster’s model, the knockdown efficiency by siRNA did not guarantee a 
complete depletion of ∆Np63 in epidermal cells in vivo. Off-target effects might 
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complicate the phenotype. The lack of a tracing marker also hindered attempts to 
follow ∆Np63-depleted cells in vivo. The overexpression approach from Romano’s 
model, on the other hand, did not take into account the existence of ∆Np63β and γ in 
addition to the α isoform and potential crosstalk among the isoforms.  
To overcome these issues, we utilized the ∆Np63-conditional knockout 
(∆Np63fl/fl) mouse model generated in the Flores lab (7) to develop an in vivo 
cutaneous wound healing model to examine functions of ∆Np63 during normal 
wound repair. By crossing ∆Np63fl/fl mice to RosaM/M mice and K14CreER+ mice to 
generate ΔNp63fl/fl, RosaM/M, K14CreER+ triple mutant mice, we can specifically ablate 
∆Np63 in epidermal basal cells expressing K14. The addition of the RosaM/M alleles 
provided a fluorescence tracing marker of RFP/GFP to follow the recombination in 
vivo. The results showed that depletion of ∆Np63 in epidermal cells delays wound 
healing process in vivo. While ethanol-treated mice (ΔNp63fl/fl) displayed a full re-
epithelialization over wounded sites 4 days post-wounding, tamoxifen-treated mice 
(ΔNp63∆/∆) still had open wounds even 8 days after wounding (Figure 10C-E). Koster 
et al. reported a similar phenotype observed in their ∆Np63-knockdown mouse 
model 96 hours post-wounding (158), further suggesting an important role of ∆Np63 
in normal wound repair. Notably, these ∆Np63-deficient epidermal cells did not 
exhibit defects in cell proliferation (Figure 11). This observation is in accordance with 
previously published data from our lab in which ∆Np63-deficient epidermal cells 
showed high BrdU staining (7, 158), whereas Romano et al. documented an 
opposite phenotype in which ∆Np63-deficient epidermal cells exhibited reduced 
proliferative capacity in their ∆Np63-knockout model (5). These discordant findings 
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might arise different approaches used to make the ∆Np63-knockout model in which 
Chakravarti et al. deleted the 3’ exon of ∆Np63 transcript (7), while Romano et al. 
replaced the 3’ exon with GFP (5). Since ∆Np63-depleted epidermal cells still 
maintained high proliferative capacity 8 days after wounding, but failed to re-
epithelialize wounded sites, I asked whether a complete induction of EMT in these 
cells upon ∆Np63 loss delayed the healing process. In fact, ∆Np63-depleted 
epidermal cells (GFP positive) at wounded sites displayed decreased E-cadherin 
and increased Vimentin expression (Figure 12), indicating occurrence of EMT in 
these cells. Thus, a complete EMT instead of a “partial” EMT upon ∆Np63 depletion 
prevents migrating keratinocytes to reverse to epithelial state in order to fully re-
epithelialize the wounds. However, there is no evidence whether the loss of ∆Np63 
would slow down or completely block wound healing. I attempted to extend the 
experimental time points longer than 8 days to determine whether the wounds would 
eventually heal. Unfortunately, the mice died after 10 days post-wounding. Possibly, 
there are potentials that wounded sites would eventually heal since dermal stem cell 
compartments in the hair follicles also contribute to replenish damaged cells during 
wounding (73). Taken together, our data support a model in which impaired function 
of ∆Np63 delays wound healing process in vivo through regulation of EMT program.  
 
6.1.3 ∆Np63 modulates EMT via regulating transcription factors, Twist1 and 
Lef1  
I have demonstrated that ∆Np63 regulates EMT in epidermal cells via 
modulating several EMT-associated transcription factors, including Twist1, Snail1, 
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Zeb1 and Lef1. Notably, induction of Twist1 and Lef1 expression was also observed 
in ∆Np63-depleted epidermal cells at wounded sites during wound healing process 
(Figure 13), suggesting the involvement of these transcription factors in ∆Np63-
regulated EMT during wound repair. In order to further explore mechanisms of action 
of ∆Np63 in modulating these factors, I first examined whether there is a direct 
transcriptional regulation of ∆Np63 to these genes. Nevertheless, no direct binding 
at the promoters of Twist1 and Lef1 was observed (Figure 12F-G), suggesting an 
indirect regulation of ∆Np63 on the expression of these genes.  
microRNAs have been intensively shown to involve in regulatory networks of 
EMT-associated transcription factors (41, 60). Furthermore, ∆Np63 has been 
reported to globally modulate microRNA biogenesis via direct transcriptional 
activation of DGCR8 (7), proposing a possible regulation of Twist1 and Lef1 by 
∆Np63 via microRNAs. By performing a RNA-microRNA pair analysis on our 
available RNA-sequencing and microRNA-sequencing data on wild type and   
∆Np63-/- keratinocytes (7), I found a network of ∆Np63-induced microRNAs that 
potentially regulate Twist1, Lef1 and Zeb1 in epidermal cells, including miR-98-3p 
and miR-34a-5p (Figure 15A). Further work showed that ∆Np63 indeed inhibits 
expression of Twist1 and Lef1 through miR-98-3p and miR-34a-5p in keratinocytes, 
respectively (Figure 16A-D). Subsequently, overexpression of miR-98-3p and miR-
34a-5p in ∆Np63-/- keratinocytes reduced migration and invasion capacity (Figure 
16E-F), further confirming a ∆Np63/microRNAs/Twist1 and Lef1 axis in modulating 
EMT and cell migration, invasion.  
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Although the induction of a partial EMT during wound healing with cells at the 
migratory front expressing Vimentin and Fsp1 has been reported (159), the 
expression of Twist1 and Lef1 during wound repair is distinctive for ∆Np63-deficient 
keratinocytes since I did not observe increased expression of either Twist1 or Lef1 at 
day 1 after wounding in ethanol-treated group (Figure 13). Twist1 is one of the 
master drivers of EMT and has been implicated as an oncogene in multiple cancers 
(160). However, few microRNAs have been identified to regulate Twist1 expression 
during EMT, including let-7d, miR-29b and miR-214 (67-69). Those microRNAs did 
not come up in our RNA-microRNA functional pair analysis.  Instead, miR-98-3p was 
connected to Twist1 in our analysis. TargetScan predicted Twist1 as a potential 
downstream target of miR-98-3p. My data also confirmed that the overexpression of 
miR-98-3p in ∆Np63-/- keratinocytes reduced expression of Twist1, suggesting 
regulatory activity of miR-98-3p to Twist1. Interestingly, miR-98 precursor is a 
member of let-7 family, and let-7d has been shown to repress EMT via down-
regulating Twist1 (69). In addition, a recent study revealed that let-7b 
overexpression inhibits re-epithelialization and delays wound healing through 
repression of IGF2BP2, then preventing migration in keratinocytes (161). These 
findings further support our data on important regulatory function of a ∆Np63/miR-
98/Twist1 axis in normal wound repair. Likewise, Lef1 is a transcription factor 
involved in the Wnt/β-catenin signaling pathway and also a known modulator of 
EMT. During EMT program, Lef1 represses expression of E-cadherin independent of 
β-catenin recruitment (162). miR-34a has been demonstrated to regulate expression 
of Lef1 in several cancers (163). In this study, I identified miR-34a as a downstream 
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target of ∆Np63, exerting its regulation on EMT during wound healing via repressing 
Lef1 in epidermal cells.  
In summary, this part of my work identified ∆Np63 as a master regulator of 
EMT in epidermal cells via modulating expression of major EMT-drivers, including 
Twist1 and Lef1. A complete activation of an EMT program in epidermal cells upon 
∆Np63 depletion leads to a delay in wound repair, further supporting the pivotal roles 
of ∆Np63 in normal skin development and homeostasis. The identification of two 
novel ∆Np63/microRNA axes in regulating EMT in epidermal cells is particularly 
significant given the fact that microRNAs play crucial roles in wound healing process 
and have been proposed as promising therapeutic targets to treat chronic wounds 
(164). Hence, both miR-98-3p and miR-34a-5p  are potential novel targets for 
treatment of chronic wounds.  
 
6.1.4 Pleiotropic roles of ΔNp63 in tumor development and progression 
Although numerous studies have explored isoform-specific functions of p63 in 
cancers, a conclusive answer is still missing due to the existence of multiple 
isoforms with opposing functions and an intricate regulatory network among the 
isoforms (4, 18, 35). With a novel approach to perform a pan-cancer analysis using 
TCGA and unique transcriptome profiles generated from TAp63-/- and ΔNp63-/- 
epidermal cells, we found a consistent tumor suppressive pattern of TAp63 across 
multiple cancers in both tumor development and progression, whereas ∆Np63 
exhibits pleiotropic roles as either an oncogene or a tumor suppressor in different 
types and stages of cancers. Particularly, ∆Np63 demonstrates tumor-promoting 
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activity during the development of 7 cancers, including some of the most prevalent 
cancers such as breast cancer (BRCA), bladder cancer (BLCA), lung 
adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) (Figure 17B). 
The oncogenic functions of ∆Np63 have been elucidated in thymic lymphomas via 
∆Np63/TAp63/IAPP axis and in cutaneous squamous cell carcinomas (cSCC) via 
∆Np63/DGCR8/microRNAs axis (25, 27). Unpublished data from the Flores lab have 
also unveiled tumor-promoting roles of ∆Np63 in LUAD and LUSC. Little has been 
known regarding mechanisms of action of ∆Np63 in the development BRCA and 
BLCA. A recent study revealed that ∆Np63 promotes tumor initiating cells in basal-
like mouse mammary tumors via direct transcriptional regulation of Fzd7, a 
component of the Wnt signaling pathway (143), further supporting our TCGA data on 
an oncogenic role of ∆Np63 in breast cancer development. More interestingly, our 
TCGA pan-cancer analysis also identified ∆Np63 as a tumor suppressor in the 
development of kidney clear cell (KIRC), heck and neck squamous cell carcinoma 
(HNSCC) and stomach adenocarcinoma (STAD). This finding in HNSCC is 
conflicting with published studies on p63 activities in HNSCC where ∆Np63 is often 
found to be overexpressed and exerts its tumor-promoting functions via suppression 
of p73-induced apoptosis (125, 126, 165, 166), suggesting a perplexing involvement 
of ∆Np63 in HNSCC and the necessity of further work to provide a complete insight 
into how ∆Np63 functions in HNSCC.  
In contrast with its oncogenic roles in cancer development, ∆Np63 shows a 
prevalent tumor suppressor role in 5 out of 6 cancers during tumor progression, 
including kidney renal clear cell (KIRC), kidney papillary (KIRP), kidney 
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chromophobe (KICH), bladder cancer (BLCA), and low grade glioma (LGG). 
Strikingly, BLCA is the only cancer in which ∆Np63 exerts its oncogenic functions 
during tumor development, but tumor suppressive roles during tumor progression. 
Even though the contribution of ∆Np63 in the development of BLCA remains elusive, 
the loss of p63 has been documented in invasive bladder cancer and is associated 
with tumor progression (167). Importantly, ΔNp63 depletion in epithelial-like bladder 
cancer cells promotes EMT, increasing cell migration and invasion, while the 
overexpression of ΔNp63 in mesenchymal-like bladder cancer cells elicits MET and 
suppresses invasion (31). These data support a model in which ΔNp63 exhibits a 
two-faceted role during cancer development and progression.  
We further employed these distinct signatures to predict patient survival in 
BLCA, KIRC, KIRP and LGG. High grade/stage tumors of BLCA, KIRC, KIRP and 
LGG showed the loss of ΔNp63 activities when tumors progressed to more 
advanced stages. Particularly, KIRC and LGG patients with high ΔNp63 activity had 
significantly better survival than patients with lower activity (Figure 24), proposing 
ΔNp63-driven signature as a potential prognosis tool for p63-isoform specific 
therapeutic interventions. The enrichment of pluripotency, EMT and ECM 
remodeling-related pathways in the ΔNp63-driven signature may be accountable for 
the association between the loss of ΔNp63 activities and tumor progression since 
these pathways have been implicated in cancer progression and metastasis (Figure 
25).  
Of note, our approach of utilizing TAp63- and ΔNp63-driven signatures 
derived from mouse epidermal keratinocytes and comparing them to expression 
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profiles across various cancer types might rise concerns regarding cross-species 
comparison and differential basal expression of TAp63/ΔNp63 in different tissue 
types. Nonetheless, our approach aimed to investigate specific functions of 
TAp63/ΔNp63 in each type of cancer based on significance, directionality and 
enrichment concordance between their transcriptional activities and development or 
progression signatures from each tumor type regardless of their basal expression 
level in those tumors. In fact, our data showed a correlation between ΔNp63 basal 
expression and its transcriptional activities as either an oncogene or tumor 
suppressor indicated in our analyses (Figure 19A). Additionally, in this study, we 
chose ΔNp63-driven signatures derived from ΔNp63-/- keratinocytes where ΔNp63 is 
highly expressed and has been shown to play pivotal roles in modulating 
differentiation and homeostasis of these cells as starting materials. We do not rule 
out the possibility that different starting materials can result in different ΔNp63-driven 
signatures. Yet, by using this ΔNp63-/- signature, we aimed to obtain the most 
complete network of its downstream targets possible that can be utilized as a 
platform for comparison of its transcriptional activities in various tissue types. The 
fact that some cancers, such as BRCA and BLCA, can be sub-divided into distinct 
molecular subtypes with different expression level of p63 may complicate the 
outcome of our study in which we did not specifically investigate functions of ΔNp63 
in different subtypes of BRCA and BLCA. However, as aforementioned, since our 
method is based on comparison of ΔNp63-driven transcriptional signature, not 
ΔNp63 basal level, we believe that our work still provides potential prediction tools to 
further stratifying patients into groups that can benefit from p63-isoform specific 
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targeted therapy. This is particularly important in the context of p63-related pathways 
have increasingly been implicated in re-classifying cancers into distinct molecular 
subtypes (125, 126).  
 
6.1.5 ΔNp63 activates an oncogenic program through transcriptional 
regulation of its downstream target, Lef1  
To further understand the molecular switch that dictates oncogenic or tumor 
suppressive activities of ΔNp63 in cancer, we identified Lef1 as a downstream target 
of ΔNp63 in BRCA, LUSC and KIRC (Figure 21 and Figure 23). In BRCA and LUSC 
cell lines, ΔNp63 exerts its tumor-promoting activity through transcriptional activation 
of Lef1. Knockdown of Lef1 in these cells mimicked the effects of ΔNp63 depletion 
on reducing anchorage-independent growth of cancer cells. Overexpression of Lef1 
in ΔNp63-depleted cells rescued the phenotype (Figure 22), further confirming the 
activation of a ΔNp63-dependent oncogenic program via Lef1 in BRCA and LUSC. 
In HCC95 LUSC cell line, ΔNp63/Lef1 axis demonstrated significant tumor-
promoting effects only in anchorage-independent growth but not cell proliferation, 
suggesting the uncoupling of ΔNp63-induced tumor initiating capacity and cell 
growth in LUSC. In Caki-1 KIRC cell line with undetectable expression of ΔNp63, 
ΔNp63 exhibits tumor-suppressive role in decreasing anchorage-independent 
growth (Figure 20I-L). Although Lef1 is still a downstream target of ΔNp63 in Caki-1 
cells, it fails to exert ΔNp63 tumor-suppressive functions in these cells, indicating the 
involvement of other alternative pathways.  
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As mentioned before, Lef1 is a component of Wnt signaling pathway and has 
been implicated in multiple cancers (162). Particularly, Lef1 has involved in 
promoting breast cancer progression and metastasis through various mechanisms 
(168-170), which is in line with our finding of the oncogenic ΔNp63/Lef1 axis in 
BRCA. On the other hand, functions of Lef1 in LUSC and KIRC remain large 
unknown. Notably, I found that ΔNp63 positively regulates Lef1 in these cancer cells, 
whereas ΔNp63 represses expression of Lef1 via miR-34a-5p in basal epidermal 
cells. These discrete observations in normal and cancer cells on the regulatory 
effects of ΔNp63 on Lef1 prompted a question on cell type-specific transcriptional 
activity of ΔNp63. When ΔNp63 was knocked down in normal mammary epithelial 
cells MCF10A, I also observed an increased in Lef1 expression, while depletion of 
ΔNp63 in MCF10DCIS breast cancer cells decreased level of Lef1 (data not shown), 
further suggesting distinct transcriptional regulatory activities of ΔNp63 on certain 
subsets of its downstream targets. Especially, ΔNp63 shows no direct transcriptional 
regulation to the promoter of Lef1 in epidermal cells, but regulates its expression via 
microRNA network, indicating other microRNAs rather than miR-34a may be 
involved in ΔNp63-induced expression of Lef1 in BRCA, LUSC and KIRC cells.  
Taken together, this study constitutes the largest analysis of ΔNp63 
transcriptional network across multiple cancers from TCGA platform. With this pan-
cancer analysis, we revealed a ΔNp63-driven signature from ΔNp63-/- keratinocytes 
that can predict cancer development, progression, and patient survival. Our findings 
elucidate a dual role of ΔNp63 as either a tumor suppressor or an oncogene in the 
development of cancer, and its regulation of Lef1 is essential for its oncogenic 
  
141  
functions in BRCA and LUSC. Likewise, ∆Np63 consistently acts as a suppressor of 
cancer progression, which is in accordance with published data in multiple cancers. 
Moreover, the ∆Np63-driven signatures identified in our integrative bioinformatics 
analyses can stratify clusters of patients with differential expression profiles for 
pluripotency, ECM and EMT-associated markers that can be beneficial for p63-
isoform specific treatment. 
 
6.1.6 Dynamic regulation of ∆Np63 in breast cancer progression and 
metastasis 
Given its crucial roles in epithelial cells and high expression in mammary 
glands, there have been several studies investigating the roles of ∆Np63 in the 
progression and metastasis of breast cancers (29, 32, 120, 143). However, the 
answer on whether ∆Np63 is an oncogene or tumor suppressor in breast cancer 
remains elusive due to conflicting data reported. Chakrabarti et al. and Franco et al. 
agreed on a tumor-promoting role of ∆Np63 in breast cancer formation (120, 143). 
Franco et al. and Giacobbe et al. also provided evidence for ∆Np63 as a promoter of 
breast cancer metastasis through different pathways (32, 120). Conversely, 
Bergholz et al. showed that ΔNp63 inhibits cell invasion and metastasis in breast 
cancer by negatively regulating Erk signaling via direct transcriptional activation of 
MKP3 (29). These discordant observations may arise from the fact that these 
studies utilized different systems most of which are in vitro assays. They also failed 
to examine the contributions of ΔNp63 from tumor formation to subsequent 
metastatic colonization as a complete process instead of only looking into snapshot 
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events during that process. Particularly, while our pan-cancer analysis from TCGA 
platform also pointed out oncogenic role of ΔNp63 during tumor development, we 
did not obtain significant data for tumor progression (135). Therefore, it is essential 
to develop an in vivo system that allows us to investigate mechanisms of action of 
ΔNp63 from primary tumor establishment to metastatic colonization to distant 
organs, especially when there are evidences for the pleiotropic roles of ΔNp63 in 
tumor development and progression from various studies. Interestingly, my data on 
the clinical association of ΔNp63 and breast cancer progression revealed the loss of 
ΔNp63 in high stage breast cancer samples, together with the correlation with poor 
survival (Figure 27). Further, I also observed an increase in the number of primary 
tumors having low expression of ΔNp63 while their corresponding metastases still 
retained high level of ΔNp63 in higher stage samples (Figure 28). These data further 
suggest a two-faceted role of ΔNp63 in the development of primary tumors and 
establishment of distant metastases.  
In fact, by utilizing an in vivo inducible knockdown system for ΔNp63, I found 
that ΔNp63 is essential for not only formation and growth of breast primary tumors 
but extravasation and lung colonization as well (Figure 31Figure 32). These findings 
are in line with previous reports on the oncogenic roles of ΔNp63 in promoting tumor 
growths in multiple cancers, including breast cancer (25, 27, 120, 135, 143). 
Strikingly, the knockdown of ΔNp63 in established tumors led to increased 
metastatic frequency to the lung, indicating a suppressive role of ΔNp63 in 
intravasation of invading tumor cells. Further, a dynamic regulation of ΔNp63 in 
which ΔNp63 was down-regulated in established tumors for a period of 3 weeks, 
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then brought back up for 3 more weeks showed highest metastatic colonization to 
the lungs (Figure 33). More importantly, all metastatic colonies in the lungs exhibited 
high expression of ΔNp63 regardless of treatment groups, suggesting the 
indispensable role of ΔNp63 for circulating tumor cells to establish new tumors at 
distant sites. The high expression of ΔNp63 in metastases arose from ΔNp63-
depleted cells indicates two possibilities. First, the ΔNp63-depleted circulating cells 
may gain expression of ΔNp63 via other alternative pathways that bypass the effects 
of the shΔNp63. Second, since the system is an inducible knockdown using shRNA, 
there is chance of inefficient knockdown in a subset of tumor cells. However, 
regardless of the underlying reasons, the high expression of ΔNp63 in all 
metastases further confirms essential roles of ΔNp63 in metastatic establishment. 
This is in accordance with the facts that ΔNp63 expression is crucial for the 
maintenance of epithelial characteristics and that the reversion to epithelial state of 
circulating tumor cells arrested at distant organs is important for metastatic 
colonization (79, 99). These intriguing findings support a two-faceted role of ΔNp63 
in breast cancer progression and metastasis in which ΔNp63 is required for tumor 
cell growth at both primary sites and distant organs, whereas losing its expression in  
a certain subset of invading cells in the primary tumors elicits intravasation into the 
circulation. Subsequent re-expression of ΔNp63 in circulating cells facilitates 
colonization to the lungs. The loss of ΔNp63 in primary tumor cells may elicit an 
EMT program to increase cell migration and invasion, subsequently promoting 
intravasation. This model can explain the opposing results from studies trying to 
understand functions of ΔNp63 in the development and metastasis of breast cancer. 
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In Bergholz’s study, the authors knocked down total p63 in transformed mammary 
epithelial cells and saw increased in metastatic incidence to the lungs when injecting 
the cells via tail vein (29). However, by using a shRNA for total p63, this approach 
did not take into account the existence of TAp63 isoforms and dominant negative 
effects of ΔNp63 over TAp63 that might complicate the phenotype. Previously, 
Cheung et al. proposed a model for collective invasion in which leader cells at the 
invading front often express K14 and p63, suggesting important contributions of p63 
in initiating collective invasion of breast cancer (122). Nonetheless, we do not find 
these observations conflicting with our proposed model in which the loss of ΔNp63 
may facilitate invasion and intravasation of single tumor cells. In fact, given the 
intricate interplay between the two modes of collective and single cell invasion in 
metastatic dissemination, our study and others suggest that ΔNp63 may function as 
a molecular switch between the two modes of invasion. Perhaps, ΔNp63 and K14 
high expression elicits a transition in tumor cells from luminal to basal state and 
triggers collective invasion in luminal breast cancer, whereas a reduction in ΔNp63 
level in ΔNp63-expressing tumor cells can initiate an EMT program and promote 
invasion. Our subsequent findings on the regulatory network between TGFβ and 
ΔNp63 further emphasize possible involvement of ΔNp63 as a molecular switch 
between collective and single cell invasion.  Although Cheung et al. provided 
evidence for a collective invasion program led by K14-expressing cells in HER2+ 
and basal breast cancer model, the authors failed to correlate K14 with p63 
expression in the leader cells in these models and to examine whether p63 directly 
involves in regulating K14 expression in these cells (122). A follow-up study from the 
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same group demonstrating that polyclonal metastases arise from K14-expressing 
cell clusters also did not investigate the relevance of p63 in this context (103). Given 
heterogeneous expression status of p63/ΔNp63 in different breast cancer cell 
lineages, it is important to consider their basal level prior to manipulation their 
expression. Several highly metastatic basal breast cancer cell lines, such as MDA-
MB-231 and MDA-MB-468, do not express detectable level of ΔNp63 (data not 
shown), suggesting that these cells may harbor genetic alterations that support them 
to bypass the regulation of ΔNp63 during metastatic dissemination.  
Therefore, attempts to classify cancers into different molecular subtypes 
using integrated cross-platform analyses provided additional information for future 
research on the contribution of ΔNp63, and p63 in general, in cancer development 
and progression (125, 126). Moreover, given the intricate role of ΔNp63 in different 
stage of breast cancer, it is essential to consider its specific function at each step of 
tumor progression and metastasis. The utilization of different models, including in 
vitro, ex vivo 3D organoid cultures and in vivo, will be also beneficial in obtaining a 
comprehensive insight into perplexing functions of ΔNp63 in cancers. This is 
particularly critical for the application of p63 isoform-specific therapeutic treatments 
in which inhibiting ΔNp63 will result in the regression of tumors, yet pose a possibility 
of increasing metastasis, especially when dormant disseminating cells have been 
increasingly considered as a primary cause for tumor recurrence in cancer patients 
(114).  
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6.1.7 TGFβ-induced microRNAs regulate ΔNp63 expression in breast cancer 
Since ΔNp63 exhibits a complex two-faceted role in breast cancer 
progression and metastasis, it is critical to determine underlying regulatory 
mechanisms that dictate ΔNp63 expression and functions. The connection between 
TGFβ signaling and ΔNp63 identified in my study reveals a novel regulatory network 
for ΔNp63 in breast cancer. Through my work, TGFβ signaling represses expression 
of ΔNp63 at post-transcriptional level in both normal mammary epithelial cells and 
breast cancer cells via canonical Smad-dependent pathway (Figure 34). Differential 
expressed microRNAs upon TGFβ treatment included several known targets of 
TGFβ signaling such as miR-181, miR-145 and miR-21 (153), further confirming the 
activation of TGFβ signaling in these cells. Intriguingly, 4 TGFβ-induced microRNAs 
were identified as upstream regulators of ΔNp63, including miR-22-3p, miR-30a-5p, 
miR-203a-3p and miR-222-3p. These microRNAs directly bind to 3’UTR of TP63 and 
regulate expression of ΔNp63 (Figure 36). Especially, the inhibition of 4 microRNAs 
or combination of miR-30a-5p and miR-203a-3p, but not any single microRNA, 
rescued inhibitory effects of TGFβ on ΔNp63 expression, suggesting synergistic 
effects of those microRNAs in regulating ΔNp63 downstream of TGFβ signaling 
(Figure 38).  
Given the complex nature of TGFβ signaling in metastatic cancer and that it is 
often difficult to monitor TGFβ activity in vivo, numerous studies have unveiled 
various downstream pathways of TGFβ signaling and its intricate crosstalk between 
tumor cells and surrounding microenvironment (171). Activated TGFβ signaling has  
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Figure 38: TGFβ-induced microRNAs modulate ΔNp63 expression. TGFβ binds 
to TGFβRI to activate phosphorylation and translocation to the nucleus of Smad2/3 
complex. p-Smad2/3 in the nucleus binds to the promoters of miR-22, miR-30a, miR-
203a and miR-222 to upregulate their expression. These microRNAs are then 
processed and exported to the cytoplasm. In the cytoplasm, these microRNAs bind 
to 3’UTR of TP63 and down-regulate translation of ΔNp63 protein.  
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been strongly associated with increased metastatic dissemination via induction of 
EMT program in tumor cells (151, 152, 172, 173). EMT-related transcription factors, 
such as Snail1/2 and Zeb1/2, are downstream targets of TGFβ signaling (173). Yet, 
impaired TGFβ signaling cascade also resulted in enhanced metastasis (174, 175). 
More interesting, TGFβ has been shown to function as a molecular switch between 
collective and single cell invasion programs in breast cancer (107), further 
emphasizing pleiotropic roles of TGFβ in metastatic dissemination. Previous study 
from Adorno et al. demonstrated that overexpression of TAp63 and ΔNp63 in p53-
mutant triple negative breast cancer cell line MDA-MB-231 abrogated TGFβ-induced 
migration in these cells. The authors then unveiled that mutant-p53/p-Smad2 formed 
a  ternary complex with p63 to antagonize its inhibitory effects on TGFβ-induced 
metastasis (176). My recent data revealed ΔNp63 as a downstream target of Smad-
dependent TGFβ signaling. Further, I proposed a model in which a transient and 
localized activation of TGFβ signaling at the primary tumors triggers EMT and 
increases invasion and intravasation of tumor cells into the circulation, whereas the 
loss of activated TGFβ at distant sites facilitates metastatic colonization via re-
expression of ΔNp63 (Figure 39). This model, together with Giampieri’s work (107), 
supports TGFβ/ΔNp63 axis as a binary switch for tumor cells to transition between 
different states (epithelial versus mesenchymal) and modes of invasion (collective 
versus single cell) in a highly dynamic fashion, which ultimately favors metastatic 
dissemination. In my opinion, by employing a regulatory network of signaling 
cascade such as TGFβ to modulate ΔNp63, a critical modulator of cell fate and 
differentiation, tumor cells have ability to quickly response to changes in the 
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surrounding microenvironment in order to adapt, survive and thrive. However, we 
also do not overlook the fact that our model may not be able to explain metastasis-
promoting effects of TGFβ signaling often observed in breast cancer. This could be 
due to other alternative downstream pathways that TGFβ exploits to drive 
metastasis, such as initiation of an EMT program independent of  ΔNp63 via direct 
transcriptional activation of Snail and Zeb as mentioned before. Additionally, 
mutation status of p53 and basal level of p63 in tumor cells also contribute to the 
regulatory network of TGFβ and p63 in cancer metastasis (176). In the presence of 
mutant p53, ΔNp63 has been shown to oppose TGFβ-induced metastasis. Our 
findings on the inhibitory effects of TGFβ on ΔNp63 suggest a potential negative 
feedback loop in which cancer cells may exploit to overcome antagonistic activities 
of  ΔNp63 in  TGFβ-induced metastatic dissemination. In addition, whether TGFβ-
induced downregulation of ΔNp63 in the primary tumor cells is a cell autonomous 
phenotype or a result of signaling cascades received from the local 
microenvironment requires further investigation. This is particularly critical when 
interactions among tumor cells and stromal fibroblasts have been shown to have 
significant effects on the outcome of TGFβ signaling in certain biological contexts 
(171).  
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Figure 39: Proposed working model for the regulatory axis of TGFβ/ΔNp63 in 
breast cancer metastasis 
 
Among the 4 microRNAs, miR-203a-3p is a known modulator of ΔNp63 
during epidermal terminal differentiation in the skin (39). The identification of this 
microRNA as a downstream target of TGFβ signaling and its inhibitory effect on 
ΔNp63 expression in breast cancer indicates a consistent role as a modulator of 
ΔNp63 across different cell types. In breast cancer, the roles of miR-203 are still 
debatable. Studies have shown its function as either a suppressor or promoter of 
breast cancers (177, 178), suggesting a perplexing role of this microRNA in breast 
cancer. Similarly, tumor-promoting and tumor-suppressive roles of miR-22 have also 
been documented (179-181). miR-30a, on the other hand, has been consistently 
demonstrated as a suppressor of breast cancer cell growth and metastasis (182-
184). Conversely, miR-222 has been implicated as oncogenes in breast cancer 
metastasis by promoting EMT in basal-like breast cancer (185, 186). These 
contradictory findings indicate a more complex regulatory network involving these 
microRNAs in breast cancer, which partly explains why the inhibition of single 
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microRNA could not rescue expression of ΔNp63 upon TGFβ induction. Of note, 
since these microRNAs bind to the 3’UTR of TP63, both isoforms of ΔNp63 and 
TAp63 will be potentially targeted. Given the predominant expression of ΔNp63 and 
the frequent loss of TAp63 in cancers, these microRNAs presumably have the most 
effect on modulating ΔNp63 level. However, as ΔNp63 transcriptionally represses 
TAp63 and promotes tumorigenesis (25), we do not rule out a possibility that by 
using these microRNAs to target ΔNp63, we will possibly prevent the upregulation of 
TAp63 upon ΔNp63 depletion, which may hinder ΔNp63 to exert its tumor-promoting 
functions via TAp63/IAPP axis. Yet, ΔNp63 has been demonstrated to promote 
tumor development via other alternative pathways, such as modulation of 
DGCR8/microRNAs axis or transcriptional regulation of Fzd7 in Wnt signaling (27, 
143). Hence, in my opinions, despite of potential effects on TAp63, our approach of 
utilizing these microRNAs to target ΔNp63 is still able to elicit its downstream effects 
on tumorigenesis. In fact, I further showed that overexpression of miR-203a reduced 
breast tumor growth in vivo (data not shown), suggesting that targeting both ΔNp63 
and TAp63 by microRNAs resulted in the same phenotype as directly targeting 
ΔNp63. In addition, the mechanisms of action of ΔNp63 during metastatic 
dissemination have also been shown through various pathways that do not involve 
TAp63 (29, 32, 94-96, 120, 154). Thus, I reason that our approach still provides 
useful tools to target ΔNp63. Apparently, further investigations into detailed 
regulatory mechanisms of TGFβ/microRNAs/ΔNp63 axis are required for a 
comprehensive understanding on how to modulate this axis in favor of developing 
treatments for metastatic breast cancer.  
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Together, this part of my work unveiled the importance of a dynamic 
regulation of ΔNp63 in breast cancer progression and metastasis. Specifically, while 
∆Np63 is required for primary tumor growth of breast cancer, the loss of ΔNp63 in 
tumor cells at primary sites promote the dissemination of tumor cells into circulation. 
In addition, ΔNp63 expression is essential for circulating tumor cells to colonize and 
form macro-metastases at distant organs. Importantly, I identified a novel regulatory 
network of TGFβ and microRNAs to modulate expression of ΔNp63 in breast cancer. 
These microRNAs are potential targets for biomarkers and therapeutic intervention 
through TGFβ/microRNAs/ΔNp63 axis to diagnose and treat metastatic breast 
cancer.  
 
6.2 Future directions 
Throughout my work, I demonstrated an intricate network of functions of 
ΔNp63 in regulating EMT, cancer progression and metastasis. These findings further 
emphasize the importance of understanding isoform-specific functions of p63 in 
particular biological contexts, and open up new directions in utilizing ΔNp63-
associated regulatory pathways to discover novel targeted therapies and diagnostic 
biomarkers.  
The identification of a ΔNp63/microRNAs/EMT-drivers axis in normal wound 
repair suggests miR-98-3p and miR-34a-3p as potential therapeutic targets to treat 
chronic wounds. In addition, our pan-cancer analysis on activities of ΔNp63 across 
different types and stages of cancers provided not only a platform for further 
research into mechanisms of action of ΔNp63 in specific cancers, but integrative 
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bioinformatics analyses that help to stratify patients using ΔNp63-driven signatures 
in order to predict patient survival and response to p63-isoform specific treatments. 
Finally, with the findings of novel TGFβ/microRNAs/ΔNp63 axis in breast cancer 
progression and metastasis, further research on clinical correlation of these 
microRNAs and ΔNp63 in different subtypes and stages of breast cancer can unveil 
potential diagnostic markers and therapeutic targets to diagnose and treat metastatic 
breast cancer. In vivo mouse models to modulate this axis are also beneficial for 
further exploration of mechanistic pathways that are important for breast cancer.  
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Appendix 1: Differential expressed microRNAs in DCIS cells treated with TGFβ  
miRNA logFC 
[TGFb/DMSO] 
AveExpr P.Value adj.P.Val 
hsa-miR-222-3p 1.852874051 10.28652968 1.08E-08 8.92E-06 
hsa-miR-181a-5p 1.536936491 8.966459296 2.34E-08 9.70E-06 
hsa-miR-190a-5p 1.317850548 5.474452591 2.68E-07 7.39E-05 
hsa-miR-30d-5p 1.130461624 6.865746322 6.44E-07 0.000133 
hsa-miR-21-5p 1.33722637 12.00925218 2.55E-06 0.000233 
hsa-miR-22-3p 1.042746137 8.846312647 2.18E-06 0.000233 
hsa-miR-29a-3p 0.969794022 11.02280024 2.70E-06 0.000233 
hsa-miR-29b-3p 0.986454772 14.54630567 2.26E-06 0.000233 
hsa-miR-30a-5p 1.366165794 7.69174656 1.83E-06 0.000233 
hsa-miR-3195 1.180313606 5.89430167 2.82E-06 0.000233 
hsa-miR-146a-5p 0.973195168 8.667250081 3.89E-06 0.000293 
hsa-miR-31-5p 1.080290369 6.598788926 6.16E-06 0.000425 
hsa-miR-181b-
5p+hsa-miR-181d-
5p 
1.053462197 6.741762331 7.37E-06 0.000469 
hsa-miR-361-3p 1.054866608 5.616265888 1.09E-05 0.000642 
hsa-miR-548d-5p 0.839881597 5.908125905 2.44E-05 0.001349 
hsa-miR-203a-3p 0.950556529 5.729458349 2.96E-05 0.00153 
hsa-miR-23b-3p 0.771975008 7.498577826 3.24E-05 0.001579 
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hsa-miR-200a-3p 0.658183652 7.763089612 7.47E-05 0.003094 
hsa-miR-4516 0.934291267 7.36976701 7.37E-05 0.003094 
hsa-miR-182-5p 0.932501672 6.00293535 8.62E-05 0.003398 
hsa-miR-424-5p 1.084347818 6.145867385 9.21E-05 0.003465 
hsa-miR-574-5p 0.820694589 6.141846943 0.000102221 0.00368 
hsa-miR-200b-3p 0.675654992 8.805182004 0.000154295 0.005323 
hsa-miR-454-3p 0.872746351 5.743828142 0.000163859 0.005427 
hsa-miR-503-5p 0.975523549 5.938059394 0.000171438 0.00546 
hsa-miR-141-3p 0.800140832 8.907529076 0.000199229 0.00611 
hsa-miR-26b-5p 0.641654495 6.731487943 0.000209159 0.006185 
hsa-miR-208a-3p 0.88556572 5.168248707 0.00024902 0.006898 
hsa-miR-575 0.929494714 5.954303571 0.000249922 0.006898 
hsa-miR-890 0.73987247 4.745216212 0.000272278 0.007272 
hsa-miR-543 0.660411144 5.842595315 0.000317425 0.008213 
hsa-miR-1244 0.705662352 5.083340114 0.000440419 0.010665 
hsa-miR-548j-5p 0.75946626 4.540336558 0.000450803 0.010665 
hsa-miR-574-3p 0.618761442 5.965869674 0.000435249 0.010665 
hsa-miR-30e-5p 0.662575328 6.067893517 0.000480997 0.011063 
hsa-miR-532-5p 0.886478227 4.983202547 0.000503638 0.011271 
hsa-miR-183-5p 0.637532302 7.587820411 0.000576733 0.012567 
hsa-miR-1193 0.778121149 4.632546463 0.000633815 0.012759 
hsa-miR-203a-5p 0.686125709 5.48522501 0.00060626 0.012759 
hsa-miR-342-3p 0.683114525 6.968303599 0.000632288 0.012759 
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hsa-miR-770-5p 0.688826731 4.865118807 0.000678022 0.012759 
hsa-miR-186-5p 0.665128366 6.496676235 0.000701143 0.012901 
hsa-miR-4524a-5p 0.781112515 4.320978851 0.000761145 0.013701 
hsa-miR-584-3p 0.61519964 5.963074174 0.000858649 0.014812 
hsa-miR-221-5p 0.918942184 4.913733762 0.000984765 0.016308 
hsa-miR-10b-5p 0.641117456 5.658376151 0.001031569 0.016426 
hsa-miR-630 0.931622917 5.501069566 0.001020109 0.016426 
hsa-miR-1915-3p 0.680540353 4.52535032 0.001129563 0.017005 
hsa-miR-412-3p 0.674832531 5.366226322 0.001121773 0.017005 
hsa-miR-433-3p 0.74922012 4.065848871 0.001123644 0.017005 
hsa-miR-1206 0.805985619 5.369483812 0.00118358 0.017193 
hsa-miR-323a-3p 0.649267499 4.785490126 0.001166974 0.017193 
hsa-miR-1266-5p 0.651261733 4.602058211 0.001565882 0.02149 
hsa-miR-365a-
3p+hsa-miR-365b-
3p 
0.599262931 8.492296957 0.00153721 0.02149 
hsa-miR-626 0.654549575 5.649534978 0.001635741 0.021498 
hsa-miR-145-5p 0.632003785 4.242116854 0.001800947 0.0233 
hsa-miR-181a-3p 0.625174269 6.626735658 0.002068456 0.0259 
hsa-miR-610 0.917830368 4.247492359 0.002090643 0.0259 
hsa-miR-101-3p 0.595136403 4.269042695 0.002273925 0.027076 
hsa-miR-1304-5p 0.628756153 4.83882076 0.002289038 0.027076 
hsa-miR-181c-5p 0.802463869 4.95101182 0.002565314 0.029501 
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hsa-miR-193b-3p 0.653152346 4.901701654 0.002725346 0.030912 
hsa-miR-1276 0.755521672 4.412776369 0.002989711 0.032806 
hsa-miR-1286 0.670731926 5.048223597 0.002973682 0.032806 
hsa-miR-495-3p 0.662074005 5.578324049 0.003011138 0.032806 
hsa-miR-96-5p 0.594252308 6.951722968 0.003299218 0.035477 
hsa-miR-1908-3p 0.78052723 4.453725003 0.003447822 0.036137 
hsa-miR-377-3p 0.767593458 4.530615321 0.003509564 0.036324 
hsa-miR-152-3p 0.649367169 4.50296469 0.003771816 0.036515 
hsa-miR-4532 0.629738302 5.569198371 0.004112009 0.037938 
hsa-miR-568 0.591596212 4.78320632 0.004123648 0.037938 
hsa-miR-1305 0.633569208 5.530270164 0.004505624 0.040551 
hsa-miR-483-5p 0.586998515 4.539141633 0.005960153 0.04919 
hsa-miR-656-3p 0.594447427 5.291681646 0.005822837 0.04919 
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Appendix 2: List of 64 TGFβ-induced microRNAs that are predicted to have 
binding sites to 3’UTR of p63 by miRWalk  
  TGFβ-induced miRNAs predicted  
bound to 3'UTRp63 by miRwalk 
1 hsa-miR-222-3p 
2 hsa-miR-181a-5p 
3 hsa-miR-190a-5p 
4 hsa-miR-30d-5p 
5 hsa-miR-21-5p 
6 hsa-miR-22-3p 
7 hsa-miR-29b-3p 
8 hsa-miR-30a-5p 
9 hsa-miR-146a-5p 
10 hsa-miR-31-5p 
11 hsa-miR-181b-5p 
12 hsa-miR-181d-5p 
13 hsa-miR-548d-5p 
14 hsa-miR-203a-3p 
15 hsa-miR-23b-3p 
16 hsa-miR-200a-3p 
17 hsa-miR-4516 
18 hsa-miR-182-5p 
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19 hsa-miR-424-5p 
20 hsa-miR-574-5p 
21 hsa-miR-454-3p 
22 hsa-miR-503-5p 
23 hsa-miR-141-3p 
24 hsa-miR-26b-5p 
25 hsa-miR-575 
26 hsa-miR-890 
27 hsa-miR-543 
28 hsa-miR-1244 
29 hsa-miR-548j-5p 
30 hsa-miR-574-3p 
31 hsa-miR-30e-5p 
32 hsa-miR-532-5p 
33 hsa-miR-183-5p 
34 hsa-miR-1193 
35 hsa-miR-342-3p 
36 hsa-miR-770-5p 
37 hsa-miR-186-5p 
38 hsa-miR-584-3p 
39 hsa-miR-221-5p 
40 hsa-miR-10b-5p 
41 hsa-miR-630 
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42 hsa-miR-1915-3p 
43 hsa-miR-412-3p 
44 hsa-miR-433-3p 
45 hsa-miR-1206 
46 hsa-miR-323a-3p 
47 hsa-miR-1266-5p 
48 hsa-miR-365b-3p 
49 hsa-miR-365a-3p 
50 hsa-miR-145-5p 
51 hsa-miR-610 
52 hsa-miR-101-3p 
53 hsa-miR-1304-5p 
54 hsa-miR-181c-5p 
55 hsa-miR-193b-3p 
56 hsa-miR-1276 
57 hsa-miR-1286 
58 hsa-miR-495-3p 
59 hsa-miR-377-3p 
60 hsa-miR-4532 
61 hsa-miR-568 
62 hsa-miR-1305 
63 hsa-miR-483-5p 
64 hsa-miR-656-3p 
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